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 Cell transplantation can be considered a regenerative therapy, an intervention 
which attempts to replace or restore the function of compromised tissue by harnessing 
innate properties of cells that cannot be replicated artificially.  For such therapies to 
succeed, it will be necessary to understand and closely match the physiological 
conditions that govern cell behaviors in vivo.  One important factor is low oxygen 
tension, termed hypoxia, which is often overlooked in vitro.  Because oxygen 
insufficiency can lead to cell death, hypoxia has traditionally been viewed as a negative 
condition.  However, hypoxia can also serve as a potent regulator of crucial cell 
behaviors involved in normal development, adaptation, and regeneration through 
transcriptional activity of hypoxia-inducible factors (HIFs).  Characterizing HIF activity, 
especially in three-dimensional tissues which can experience oxygen heterogeneities, 
will be useful in investigating how culture parameters impact local microenvironmental 
conditions to affect cell behavior. 
 In the present work, a novel fluorescent reporter system was used to detect 
cellular HIF activity in islet-like clusters of pancreatic β-cells and adipose-derived stem 
cell (ADSC) spheroids, two cell systems used in transplantation therapies.  Fluorescent 
signaling was observed in cultures incubated in reduced oxygen conditions and in large 
cultures, indicating the development of tissue size-dependent oxygen gradients.  HIF 
activity could be monitored in the same samples over time and could be correlated to 
vi 
other cell behaviors.  In β-cells, signal was observed in all clusters incubated in 1% or 2% 
oxygen and in the center of large clusters (>300μm) incubated in 20% oxygen.  In 
clusters that exhibited HIF activity, insulin secretion and cluster morphology were 
severely impaired.  In ADSC spheroids, both reduction of external oxygen concentration 
and an increase in spheroid size increased HIF activity.  Moderate HIF activity 
corresponded with increased vascular endothelial growth factor (VEGF) secretion from 
spheroids, while intense HIF activity corresponded with regional reduction of cell 
viability; therefore, an optimal size for VEGF secretion could be demonstrated.  
Altogether, the HIF reporter system represents a useful tool in monitoring cellular 
hypoxia so that culture parameters such as external oxygenation and culture size can be 
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This dissertation is concerned with presenting and discussing experimental data 
which contributes novel findings to the field of cell transplantation.  Specifically, results 
from the included studies provide a better understanding of how hypoxia develops 
within 3-dimensional (3D) cultures of pancreatic β-cells and adipose-derived stem cells 
(ADSCs) and how knowledge of this hypoxic status can be used to rationally direct 
desired cell behaviors (insulin secretion and VEGF secretion, respectively) to improve 
outcomes in transplantation therapies intended to restore lost tissue function.  The 
structure of this dissertation, then, is intended to both communicate peer-reviewed 
results from several separate studies and to make clear the underlying impetus by which 
they are unified.  The document is structured in the following manner: 
• Chapter 1 consists of a literature review intended to develop a framework 
explaining why the research was undertaken.  This includes relevant historical 
studies, recent findings and advancements in the field, and identification of 
areas in which the current knowledge appears to be incomplete.  Specifically, the 
essential role of oxygen as a both a nutrient and as a cell signaling molecule is 
first discussed.  Next, the mechanism of hypoxia-mediated regulation of cell 
behavior is explained, and it is suggested that rational control of culture 
parameters can be used to regulate hypoxic status, thus driving desired cell 
function.  A novel approach to identifying cellular hypoxia is also advocated.  
2 
Finally, the importance of hypoxic status is considered in two specific cell 
systems which exhibit potential usefulness in transplantion therapies: islet-like β-
cell clusters and ADSC spheroids.  The advantages of tracking hypoxia by use of a 
novel reporter system as well as the potential benefits of characterizing hypoxia 
in these two systems are highlighted. 
• Chapters 2-4 are research studies that have been published or submitted for 
publication in peer-reviewed research journals.  These chapters each include a 
brief introduction, description of experimental methods and design, study 
results, and discussion of the findings.  Section, figure, and reference numbering 
has been altered to conform to the formatting of this dissertation.  Chapter 2 
reports on the use of the hypoxia reporter in encapsulated islet-like clusters of β-
cells of different sizes cultured in 20% or 1% oxygen.  Chapter 3 compares 
hypoxic status, function, and viability of encapsulated clusters of the same size 
cultured in 20%, 2%, or 1%.  Chapter 4 reports how overall hypoxic status of 
ADSC spheroids, as indicated by the reporter, can be intentionally affected by 
spheroid size and culture oxygenation in order to direct optimal secretion of 
proangiogenic growth factors from the cells. 
• Chapter 5 discusses the overall findings of the previous three chapters, tying 
together the results and making an argument for the importance of considering 
oxygen tension in cell-based therapies.  The novel results of these studies as well 
as their contribution to the advancement of β-cell and ADSC transplantation are 
presented. 
3 




1.1 Oxygen’s Role as a Nutrient 
 
Oxygen is an abundant element in nature, existing commonly as colorless, 
odorless dioxygen gas (O2), or forming oxides with most other elements.  Estimates 
suggest that oxygen presently accounts for roughly 49% (wt.) of Earth’s crust and 21% 
(vol.) of Earth’s atmosphere [1 Duursma and Boissan, 1994].  Furthermore, molecular 
oxygen has been present in the environment, at varying levels, for the majority of the 
time span over which life has been evolving [2 Castresana 1995],[3 Dismukes 2001],[4 
Kump 2008],[5 Stamati 2011].  From its ubiquity, it is not surprising, then, that oxygen 
plays an integral role in the biochemical processes of most known species.  While 
certain unicellular organisms with ancient evolutionary origins have retained the 
capability to survive without oxygen, most other unicellular organisms, and virtually all 
multicellular ones, are dependent upon oxygen for survival.  Indeed, incorporation of 
oxygen into biotic biochemistry may have been a prerequisite for the development of 
metazoan life [3 Dismukes 2001],[5 Stamati 2011].  The importance of oxygen to human 
biology, for instance, is evidenced by the complex mechanisms that have evolved to 
facilitate its availability: respiratory organs (lungs) to take in oxygen, carrier molecules 
(hemoglobin) to bind it, and a circulatory system (heart and blood vessels) to distribute 
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it throughout the body.  In this regard, oxygen can be considered a nutrient, a chemical 
used in an organism’s metabolism that is required to sustain its life and which must be 
taken in from its external environment [6 Whitney 2005]. 
 
1.1.1 Aerobic Respiration 
 
In living organisms, the presence of oxygen allows for increased efficiency in 
energy production.  Organisms that do not utilize oxygen for energy production depend 
solely upon the process of glycolysis for the direct formation of adenosine triphosphate 
(ATP) and are termed “anaerobes”.  Anaerobes are typically unicellular and prokaryotic.  
Alternatively, aerobes use oxygen as the final electron receptor in the process of 
oxidative phosphorylation, a series of reactions that generate 16-18 times more ATP 
than glycolysis.  In aerobic cells, mitochondria, the organelles in which the oxidative 
phosporylation process occurs, can account for 85-90% of cellular oxygen consumption 
[7 Solaini 2010]. 
In the process of oxidative phosphorylation, pyruvate, the product of glycolysis, 
is further broken down in the citric acid cycle to produce more ATP as well as the 
reduced form of the molecules nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2), which act as energy carries (Figure 1.1).  NADH and 
FADH2 donate electrons to the electron transport chain (ETC), a series of membrane-
associated protein complexes that are sequentially reduced by the electrons, resulting 
in protons being pumped out of the inner mitochondrial compartment against their 
concentration gradient.  The electrons are finally passed to the enzyme, cytochrome-c 
oxidase (COX), which uses four electrons to catalyze the reduction of one molecule of O2 
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to two molecules of water [8 Brunori 1987].  The proton gradient generated by the ETC 
is used by the transmembrane protein complex, ATP synthase, to generate ATP (Figure 
1.2).  It is estimated that nearly 40% of the energy represented in the oxidation of 
glucose is converted to energy in the form of ATP [9 Bergamini 2004], making aerobic 
respiration a highly efficient biological reaction. 
 
 
Figure 1.1 Production of energy-carrying molecules in 
aerobic cellular respiration.  Comparison of ATP 
production in the aerobic and anaerobic processes is also 
shown.  (ADP: adenosine diphosphate; CO2: carbon 





Figure 1.2 Schematic of the ETC and production of ATP by 
proton motive force.  NADH and FADH2 initially donate 
electrons to different complexes in the ETC, resulting in 
the transfer of a different number of protons for the two 
molecules.   
 
 
1.1.1.1 Aerobic Respiration and Organismal Complexity 
The energy yield from anaerobic respiration is relatively small in comparison to 
aerobic respiration.  This energy limitation necessarily limits the diversity of molecules 
that can be produced in anaerobic species, and, in turn, restricts their potential size and 
complexity.  Raymond and Serge predicted that at least 1000 metabolic reactions which 
occur in aerobic metabolism cannot occur under anaerobic processes [10 Raymond 
2006].  Specifically, these tend to be synthesis reactions of larger, more hydrophilic 
macromolecules.    Additionally, certain molecules, such as sterols, that are essential to 
complex, compartmentalized cells, require oxygen for their biosynthesis and are thus 
typically lacking in anaerobic organisms [11 Summons 2006].  Furthermore, elevated 
metabolic levels resulting from aerobic respiration have been suggested to have 
contributed to the development of nuclear signaling pathways in eukaryotes, as many 
nuclear factors are products of respiration [12 Jiang 2010].  Thus, it is clear that the rise 
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of atmospheric oxygen and the emergence of aerobic metabolism were critical to the 
evolution of complex metazoans whose energy demands cannot be met by glycolysis 
alone [5 Stamati 2011],[12 Jiang 2010],[13 Thannickal 2009].  In fact, oxygen is noted to 
be among the most commonly-used molecules in the metabolic and biosynthetic 
processes of multicellular animals [10 Raymond 2006]. 
 
1.1.1.2 Aerobic Respiration and Reactive Oxygen Species 
 
Evolution of the ability to use oxygen in the production of energy was a boon to 
organismal complexity.  However, use of oxygen in metabolism presents a set of 
challenges for aerobic life forms.  The large energy release from the reduction of O2 to 
water is harnessed during oxidative phosphorylation in a series of less energetic 
reduction reactions in the ETC.  Electron “leak” during these steps can result in 
premature and incomplete reduction of O2 and formation of several different oxygen 
metabolites such as hydrogen peroxide (H2O2), superoxide anions (·O2
-), or hydroxide 
radicals (HO·).  These products, known as reactive oxygen species (ROS), are significantly 
less stable than molecular oxygen and interact with other biomolecules much more 
readily than O2.   
At least nine mitochondrial enzymes in the ETC have been found to measurably 
contribute to ROS production in mammalian cells [14 Andreyev 2005].  In fact, it has 
been estimated that 2-3% of the molecular oxygen utilized by mitochondria in oxidative 
phosphorylation is incompletely reduced [15 Gibson 2008].  If not neutralized, excessive 
ROS levels can be extremely toxic to a cell.  ROSs have the ability to damage lipids, 
proteins, and deoxyribonucleic acids (DNA), among other cell constituents [9 Bergamini 
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2004],[16 Chance 1955].  Furthermore, oxidative damage by ROSs to certain enzyme 
complexes involved in the ETC can cause an increased generation of more ROSs in a 
feed-forward manner.  Cellular damage caused by ROSs is collectively referred to as 
“oxidative stress” and can result in cell death.  The negative impact that ROSs can have 
on cellular function can be implied from the considerable number of protective 
mechanisms that aerobic cells have developed for detoxifying ROSs or mitigating their 




In 1772, Joseph Priestley showed that depletion of an essential element in air by 
a mouse in a sealed glass jar resulted in the animal’s death, and that a plant placed in 
the jar could restore the air’s vitality [17 Priestley 1772].  The element was subsequently 
isolated and identified as oxygen [18 Lavosisier 1789].  The word “hypoxia” (“hypo” – 
low or less, and “oxia” – referring to oxygen), then, denotes a state of reduced 
oxygenation within a biotic environment, often used to mean “oxygen insufficiency”.  In 
humans, some common causes of hypoxia within bodily tissues include environmental 
limitation (thin air), respiratory disorder, blood disorder (anemia), vascular 
damage/occlusion, and elevated metabolic use (exercise).  From Priestley’s experiment, 
it is clear that the dire, organismal-level effects of hypoxia have long been known. 
Different species can exhibit different tolerances to hypoxia.  For instance, 
loggerhead turtles, marine reptiles, have been found to dive underwater for up to seven 
hours before resurfacing [19 Hochscheid 2005], while sperm whales, marine mammals, 
can dive for thirty minutes to an hour [20 Watkins 2002].  For many common terrestrial 
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mammals, including humans, the survival time without oxygen is generally found to be 
4-6 minutes.  (Indeed, Irving estimated that the maximal theoretical store of oxygen in 
an average adult male would be completely consumed by resting metabolism in no 
more than 11 minutes [21 Irving 1939].)  Resistance to hypoxia also varies among 
different types of tissue, depending largely upon their metabolic activity and energy 
requirement.  For instance, the estimated survival times of different human tissues 
without oxygen vary widely:  brain, < 3 min.; kidney and liver, 15-20 min.; skeletal 
muscle, 60-90 min.; vascular smooth muscle, 24-72 hrs.; hair and nails, several days [22 
Leach 1998].  However, no matter the cellular or organismal tolerance for hypoxia, all 
forms of life that are dependent upon aerobic respiration succumb to oxygen 
deprivation of sufficient severity or duration.   
 
1.1.2.1 Hypoxia: Notes on Terminology 
 
  The term “hypoxia” is applied somewhat ambiguously in the biomedical 
literature, describing either an oxygen range, typically 0% – 5% O2, or a comparative 
oxygen tension that is below the physiological norm for a given tissue.  The difference is 
subtle yet relevant, as the native oxygen environment can vary significantly between 
different tissues in the body.  For instance, from Table 2.1 it can be seen that some 
tissues constantly reside in an environment that is traditionally considered hypoxic, 
while others can experience a significant reduction in oxygen from normal levels while 
remaining above an oxygen partial pressure (pO2) of 5% [23 Carreau 2011],[24 Fermor 
2007].   
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Due to such imprecise terminology, attempts to clarify the language have been 
sporadically, though increasingly, seen.  The more accurate terms “atmospheric 
normoxia” and “hyperoxia” have been used to describe atmospheric oxygen pressure, 
while “physiological normoxia”, “physioxia”, and “in situ normoxia” have been used to 
express normal physiological oxygen pressure [23 Carreau 2011],[25 Ivanovic 2009].  For 
such discriminating authors, “hypoxia” is reserved to denote an abnormally reduced pO2.  
Such descriptions are further complicated, however, by the somewhat variable reports 
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of the “physionormal” pO2 range, e.g. 3-10% [23 Carreau 2011], 2-9% [26 Simon 2008], 
3-5% [27 Semenza 2012a], 1-14% [5 Stamati 2011].  Additionally, normal tissue oxygen 
pressure can vary from individual to individual and can be affected by various activities.  
In any case, the traditional use of “normoxia” to represent atmospheric oxygen pressure 
(21%) and “hypoxia” to represent oxygen pressures below 5% persists in the vast 
majority of the published literature. 
That conditions which are traditionally viewed as “hypoxic” can be both 
physionormal and pathological depending upon the local microenvironment is a central 
theme of the present work.  In either case, oxygen tension acts as a stimulus, affecting 
cell behavior and function.  Therefore, this work will attempt to characterize “hypoxia” 
in such terms. 
 
1.1.2.2 Hypoxia: Effects of O2 Limitations on Aerobic Respiration 
 
 Lack of oxygen is lethal to cells that rely on aerobic respiration, though the 
process of hypoxic cell death is not always straightforward.  Some cellular effects of 
hypoxia can include dramatically reduced protein production and turnover, 
mitochondrial derangement, loss of osmotic balance, increased oxidative stress, and cell 
death by necrosis, apoptosis, or autophagy [7 Solaini 2010],[28 Hochachka 1996],[29 
Shimizu 1996], [30 Zhang 2008],[31 Azad 2008],[32 Kumar 2010].  As O2 is required to 
accept electrons at the end of the ETC, it would be reasonable to assume that a paucity 
of oxygen would result in the dysfunction of oxidative phosphorylation.  Indeed, in a 
traditional view, hypoxic cell death proceeds as follows: inhibition of the ETC, cessation 
of ATP production, depletion of ATP pools through utilization in cellular processes, 
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failure of membrane ion pumps, loss of osmotic balance, and, finally, necrotic cell death.  
However, more thorough investigations over the past several decades have found that 
disruption of the ETC due to oxygen limitation is not normally the precipitating cause of 
death in hypoxic cells. 
By examining the relationship between oxygen concentration and electron flux 
in isolated mitochondria, it was found that COX activity did not become oxygen limited 
until oxygen concentrations fell below <0.1% [33 Wilson 1979],[34 Erecinska 1982],[35 
Rumsey 1990].  In other words, the ETC could still function to produce ATP even at 
oxygen concentrations well below the levels of physiological hypoxia.  Interestingly, 
global cellular responses to hypoxia are often seen at oxygen concentrations in the 
range of 1-3% O2, higher than the concentration at which oxygen becomes limiting for 
ETC function [36 Schumacker 1993] [37 Budinger 1996],[38 Chandel 1997],[39 Budinger 
1998].  Such changes include reduction of energy-intensive processes, activation of 
glycolytic pathways, and changes in mitochondrial respiratory rate.  This implies, 
somewhat counter intuitively, that instead of oxygen-limited mitochondrial function 
altering cellular function, altered cell function triggered by hypoxia seems to alter 
mitochondrial function.  Indeed, it was found that cellular ATP utilization is the primary 
factor influencing respiration rate in most cells, accounting for up to 50% of the control 
over the process, while the ETC account for only 0-15% [40 Brown 1990a],[41 Brown 
1990b].   
Suppression of mitochondrial oxygen consumption in the range of 1-3% O2 is 
referred to as oxygen conformance and is a well-documented phenomenon [28 
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Hochachka 1996].  When this occurs, an increase in glycolytic respiration is usually seen.  
Though much less efficient than the aerobic process, glycolysis can proceed quickly and 
makes ATP availably directly into the cytoplasm.  Thus it can provide a significant 
amount of ATP for a cell in the short term.  However, glycolysis also uses glucose much 
more rapidly that aerobic respiration.  In conditions where both oxygen and nutrient 
availability are limited (such as ischemia, or severe hypoxia in cells with a high energy 
demand) glycolytic glucose insufficiency can result in ATP depletion, loss of osmotic 
balance, and necrosis, as predicted by the traditional view of hypoxia [42 Eguchi 1997]. 
 That the oxygen-dependent chemical reaction in the aerobic metabolic pathway 
is not oxygen-limited when cells begin to exhibit a response to hypoxia indicates that 
nutritional oxygen (i.e. oxygen as a simple metabolic substrate) cannot be responsible 
for the changes in cell behavior.  However, such adaptive behaviors are clearly a direct 
response to changes in oxygen concentration, implying that oxygen must be involved in 
affecting behavior by some other oxygen-sensitive pathways.  Thus, it is clear that 
beyond simply serving as a nutrient, oxygen must also play a role in cell signaling events.  
This role, and the mechanisms by which it is facilitated, will be discussed in the following 
section. 
 
1.2 Oxygen’s Role in Cell Signaling 
 
The ability of cells to react/adapt to low oxygen tension implies the existence of 
cellular mechanisms for sensing oxygen and subsequently transmitting signals to alter 
cell behavior.  One of the earliest examples of such signaling to be discovered was the 
ability of low pO2 to alter the ionic conductance of cells within the carotid body in the 
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carotid artery, triggering electrical signaling of the central nervous system to affect 
breathing and arterial tone [43 López-Barneo 1988].  Another such oxygen-sensitive 
response is the upregulation of erythropoietin (EPO), the hormone responsible for red 
blood cell maturation, in oxygen deficient kidney and liver cells, also investigated in the 
mid eighties [44 Bondurant 1986],[45 Schuster 1989].  Following these observations, the 
subsequent, pervading assumption held that oxygen sensing in the body was 
accomplished primarily by such variously-distributed, specialized cells.  However, work 
in the early 1990’s by the Semenza group uncovered a universal oxygen-
sensing/signaling mechanism common to all nucleated cells in humans and well 
conserved in most vertebrates.  This mechanism was determined to be the primary 
means by which all cells regulate oxygen homeostasis, adapting energy consumption to 
oxygen supply and avoiding excessive ROS formation.  Furthermore, continued research 
over the ensuing two decades has slowly revealed how low oxygen tension and the 
cellular behaviors that it drives are an ordinary and indispensible part of many cell 
functions and of normal organismal development.  As tissue engineering and 
regenerative medicine perspectives take an increasingly prominent position in the 
advancement of medical therapies, it will be essential to consider oxygen’s role not only 
as a nutrient but as a potent signaling molecule, influencing a myriad of cell behaviors. 
 
1.2.1 Hypoxia Inducible Factors: The Master Regulators of Response to Hypoxia 
 
 Hypoxia-inducible factor-1 (HIF-1), first identified by Semenza and Wang in 1992 
[46 Semenza 1992], is an oxygen-regulated transcription factor, commonly referred to 
as the master regulator of hypoxia.  Since its discovery, two other HIF-family proteins, 
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HIF-2 and HIF-3, have been identified.  Beyond simply helping cells cope with reduced 
oxygenation, HIF proteins have been found to drive important cell behaviors involved in 
embryonic development, cell commitment and maturation, and healing, as well as 
pathologies such as cancer.  As HIF-proteins appear to regulate the majority of 
observable changes in cell behavior in response to reduced oxygen tension, the 
presence of cellular HIF activity has the potential to be more instructive regarding cell 
behavior than measuring local oxygen concentration. 
 
1.2.2 HIFs: Discovery 
 
The observation of oxygen conformance in mitochondria suggested a 
widespread mechanism of oxygen sensing common to all cells [28 Hochachka 1996].  
Using DNase I protection assays to examine the mechanism of EPO responsiveness to 
oxygen in human hepatoma cells, Semenza et al. first identified a 256-base-pair region 
in the EPO gene that bound at least two anemia-induced nuclear factors and which 
conferred hypoxia inducibility when transiently expressed in other genes [47 Semenza 
1991].  Further examination of this region delineated the essential 50-nucleotide 
enhancer sequence, which was termed the hypoxia responsive element (HRE) and 
identified a nuclear factor, HIF-1α, which exhibited hypoxia-inducible binding to the HRE 
[46 Semenza 1992].  In the hepatoma cells, presence of a functional HRE resulted in a 
seven-fold increase in EPO production in response to hypoxia (1% O2). 
Maxwell et al. soon showed that the HRE elicited hypoxia-responsive 
transcription in a number of other cell types as well [48 Maxwell 1993].  Human fetal 
lung fibroblasts, human skin fibroblasts, human monocyte/macrophage cells, monkey 
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renal fibroblasts, pig retinal epithelial cells, rat aortic endothelial cells, Chinese hamster 
lung fibroblasts, Chinese hamster ovary cells, mouse renal adenocarcinomas, and mouse 
erythroleukemias were transiently transfected with a plasmid containing the HRE 
enhancer fused to a broadly active promoter and the α1-globin gene as a reporter.  In 
1% oxygen, 11 of the 12 tested lines demonstrated a 3- to 11- fold induction of α1-globin 
production, similar to the original observations in hepatomas [48 Maxwell 1993].  This 
implied that the same hypoxia-responsive nuclear factor responsible for HRE binding 
and EPO upregulation in hepatomas must be present in a range of cell types and may 
represent a widespread mechanism for response to hypoxia.  Indeed, Wang and 
Semenza observed that a number of mammalian cell types which did not express the 
EPO gene still exhibited binding of HIF-1 to DNA and that the binding site was the same 
conserved HRE sequence [49 Wang 1993a].  Weiner et al. later demonstrated HIF-1 
expression in every mammalian tissue they tested: brain, kidney, liver, heart, placenta, 
pancreas, and skeletal muscle tissue in mice, rats, and humans [50 Weiner 1996].  
Subsequent investigation has found that HIF-1 and its oxygen-sensitive regulator 
mechanism are conserved in all aquatic and terrestrial vertebrates [51 Rytkönen 2011]. 
 
1.2.3 HIFs: Structure 
 
 HIF-family proteins are heterodimeric transcription factors comprising a 
constitutively-expressed and stable β subunit and one of three constitutively-expressed 
α subunits, subject to post-transcriptional, oxygen-dependent regulation.  The β subunit 
is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT).  The α 
subunits are termed HIF-1α, HIF-2α, and HIF-3α, with HIF-1α being the most prominent 
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and most well-studied (though the importance of non-redundant activities regulated by 
HIF-2α is becoming more well-elucidated). 
 Both α and β subunits have been identified as members of the basic Helix-Loop-
Helix PER-ARNT-SIM (bHLH-PAS) family of transcription factors [52 Wang 1995].  Kewley 
et al. review the biology of this family of proteins [53 Kewley 2004].  bHLH-PAS 
transcription factors are often signal-regulated and bind to non-traditional variants of 
the classic E-box enhancer.  In the case of HIF heterodimers, the specific recognition 
sequence is the HRE found in the promoter region of target genes.  The conserved 
portion of this recognition sequence is 5’-(A/G)CGTG-3’ [54 Semenza 1996].  The PAS 
domain is named for three proteins in which the domain was originally identified: Period 
Circadian Protein (PER), ARNT, and Single-Minded Protein (SIM).  Signals mediated by 
PAS domains in various organisms include redox state, xenobiotic metabolism, light 
detection, and oxygen balance [55 Taylor 1999].   
Members of the bHLH-PAS family must dimerize to become functional and are 
defined by two major domains: 1) a bHLH domain near the N-terminus, termed the N-
terminal transactivation domain (NTAD), responsible for nonspecific dimerization [56 
Murre 1989],[57 Reisz-Porszasz 1994],[58 Ema 1996],[59 Jiang 1996a],[60 Kobayashi 
1997], with the basic region being the site of DNA binding [61 Ferré-D’Amaré]; and 2) a 
PAS homology domain which establishes dimerization partner specificity and target 
gene specificity [55 Taylor 1999],[62 Pongratz 1998],[63 Crews 1999].  In addition, HIF-α 
subunits contain an oxygen-dependent degradation domain (ODD), while HIF-1α and 
HIF-2α contain a C-terminal transactivation domain (CTAD) which interacts with 
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transcriptional co-activators to help initiate transcription [64 Jiang 1997],[65 Huang 
1998],[66 Ema 1999],[67 O’Rourke 1999],[68 Maynard 2003].  While HIF-β is known to 
interact with a number of other bHLH-PAS proteins, HIF-1α dimerizes almost exclusively 
with HIF-β.  In humans, HIF-1α is encoded by the HIF1A gene, HIF-2α is encoded by the 
endothelial PAS domain protein 1 (EPAS1) gene, and HIF-3α is expressed as multiple 
splice variants of the HIF3A gene [52 Wang 1995], [68 Maynard 2003],[69 Makino 2002]. 
 
1.2.4 HIFs: Transcriptional Activity 
 HIF-α is constitutively produced in the cytoplasm where it is rapidly degraded in 
the presence of oxygen.  When oxygen concentrations drop and HIF-α levels rise, the 
protein is translocated to the nucleus where it is free to dimerize with HIF-β [70 Chilov 
1999].  Translocation may be partially dependent upon mitochondrial succinate [71 
Brière 2005].  In the nucleus, the HIF heterodimer binds to HRE sequences in target 
genes and recruits the CREB-binding protein/p300 (CBP/p300) transcriptional 
coactivator complex to initiate transcription [66 Ema 1999],[72 Arany 1996],.  Both HIF 
stability and the ability of HIF dimers to interact with the CBP/p300 complex are 
regulated in an oxygen-dependent manner. 
 
1.2.5 HIFs: Regulation 
 
 Following its discovery, it was known that HIF-1α was regulated by oxygen but 
was not itself responsible for oxygen sensing.  Due to their direct chemical interactions 
with molecular oxygen, COX and heme proteins were first suggested as likely oxygen-
sensing candidates [28 Hochachka 1996].  (It was later shown that HIF-α can be 
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stabilized even in the absence of functional ETC machinery, including COX [73 Brunelle 
2005].)  In 2001, however, it was discovered that a member of the conserved family of 
prolyl-4-hydroxylases (PHDs) [74 Epstein 2001],[75 Bruick 2001], specifically prolyl 4-
hydroxylase 2 (P4H2) [76 Berra 2003], was the cellular oxygen sensor and regulator of 
oxygen-dependent degradation of HIF-α.  Since then, several other mechanisms of HIF 
regulation, either directly or indirectly dependent on oxygen, have been identified or 
suggested. 
 
1.2.5.1 Regulation of HIF-α Protein Stability 
 
Activation of HIF-1 is oxygen-dependent and is regulated by stability of the HIF-
1α protein subunit.  Both HIF-1α and HIF-1β messenger ribonucleic acids (mRNAs) are 
constitutively expressed intracellularly, but HIF-1α protein levels are nearly 
undetectable in normoxic cells, even when HIF-1α is overexpressed.  In hypoxic cells, 
high levels HIF-1α are observed, but HIF-1β levels are unaffected.  Both intracellular 
levels of HIF-1α and DNA binding of HIF-1 rapidly decrease upon re-introduction to 
normoxia [77 Huang, 1996]. 
Examination of HIF-1α by Ratcliffe et al. revealed a region of the protein 
between amino acids 530 and 652, the ODD, which conferred oxygen-dependent 
repression when transferred to a reporter gene system [78 Ratcliffe 1998]. They 
suggested that the mechanism of regulation may be mediated by proteolytic 
degradation.  It was later found that P4H2 was responsible for hydroxylating HIF-1α 
within this region [76 Berra 2003].  Specifically, it was shown that P4H2 hydroxylates 
two key proline residues, proline 564 [79 Ivan 2001] and proline 402 [80 Masson 2001], 
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in the ODD which allows for its recognition by the E3-ubiquitin ligase complex.  Activity 
of the HIF PHD family of enzymes is dependent on Fe2+, α-ketoglutarate (2-oxoglutarate), 
and ascorbic acid as co-factors and O2 as a cosubstrate.  In the case of HIF-1α, P4H2 
catalyzes a dioxygenase reaction in which one oxygen atom is inserted into the proline 
residue and the other is inserted into α-ketoglutarate to form succinate and CO2 [81 
Schofield 2004].  Thus P4H2 serves as the global, cellular oxygen sensor.  In the presence 
of oxygen, P4H2 mRNA is upregulated [74 Epstein 2001] and the hydroxylation reaction 
with HIF-1α proceeds.  When oxygen is limited, the reaction does not take place and 
HIF1α is not hydroxylated.  In addition, the protein, OS-9 can interact with both HIF-1α 
and P4H2 to promote degradation [82 Baek 2005].  The requirement of Fe2+ as a 
cofactor explains the ability of iron chelating agents, such as cobalt chloride and 
desferoxamine, to induce a hypoxic response in cells. 
Hydroxylated HIF-1α is recognized by the von Hippel-Lindau tumor suppressor 
protein (pVHL), the β-domain of which interacts with the hydroxylated moieties in the 
HIF-1α ODD.  The α-domain of pVHL then recruits elongin B, elongin C, cullin-2, and ring-
box 1 to form a complex which covalently links a chain of ubiquitin moieties to the ODD.  
Polyubiquitinated HIF-1α docks with the 26S proteasomal complex which selectively 
degrades ubiquitinated proteins [83 Maxwell 1999],[84 Ohh 2000].  The protein, SSAT2, 
helps to stabilize the interaction of pVHL with elongin C thus facilitating ubiquitination 
of HIF-1α. [85 Baek 2007].  Degradation by this pathway is rapid; cytoplasmic HIF-1α is 
nearly undetectable under normoxic conditions, and the half-life of stabilized HIF-1α is 
approximately 5 minutes upon cellular reoxygenation. 
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The canonical pathway of HIF protein regulation, then, is as follows: In the 
presence of oxygen, P4H2 hydroxylates HIF-1α, which can than be recognized by pVHL 
and quickly degraded by the E3-ubiquitin ligase complex.  In the absence of oxygen, 
hydroxylation of HIF-1α does not occur and intracellular levels of the molecule increase. 
 
1.2.5.2 Regulation of HIF-α Transcriptional Activity 
 
 The transcriptional activity of HIFs can also be regulated in an oxygen dependent 
manner.  HIF-α contains a nuclear localization signal in its CTAD, allowing stable HIF-α to 
rapidly bind to nuclear pore proteins and translocate into the nucleus [86 Kallio 1998].  
Once there, it is free to pair with HIF-β to form a functional HIF dimer.  Ema et al. found 
that the CTAD of HIF-α in the nucleus interacts with CBP/p300 to initiate transcription of 
target genes [66 Ema 1999].  A key asparagine residue in this region (asparagine-803 in 
HIF-1α and aspargine-851 in HIF-2α) can be hydroxylated by another hydroxylase-
domain protein, termed factor inhibiting HIF (FIH), in the presence of oxygen [87 Lando 
2002a].  The modification sterically inhibits HIF-α from interacting with CBP/p300, 
necessary components of the transcription machinery [88 Lando 2002b].  P4H2 has a Km 
for oxygen that is approximately 3 times greater than FIH; therefore, in moderately 
reduced oxygen conditions in which HIF-α is beginning to be stabilized due to declining 
P4H2 activity, FIH can still repress HIF activity by inhibiting DNA binding [89 Koivunen 
2004].   
As both major mechanisms for regulating HIF activity are hydroxylase-dependent, 
it is clear that hydroxylases are central to cellular hypoxic responses.  It is not surprising 
then that, like HIF proteins themselves, the HIF regulatory hydroxylases also appear to 
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be highly conserved in vertebrates.  Figure 1.3 summarizes how hydroxylase-domain 




Figure 1.3  Oxygen-dependent mechanisms of HIF regulation. In normoxia, 
HIF-1α is constitutively expressed but protein levels are kept low by rapid 
ubiquitination and proteosomal degradation.  Activity of any non-
degraded HIF-1α is suppressed by the failure of the p300 co-activator to 
bind.  In hypoxic conditions, oxygen dependency of both hydroxylases, 
P4H2 and FIH, prevents HIF-1α modification, inhibiting degradation and 
allowing for dimerization and binding of co-activators. 
 
 
1.2.5.3 Additional Factors in HIF regulation 
 
 Though there seems to be limited redundancy in HIF regulation, several factors 
other than PHDs can influence HIF activity in both oxygen-sensitive and oxygen-
independent manners.  Specifically, agents which have the ability to affect HIF mRNA 
stability, PHD catalytic activity, pVHL affinity/polyubiquitination, and complexing of 
HIF/BCP/p300/HRE can modulate HIF activity.  Several miRNAs and mRNA-destabilizing 
proteins have been shown to interfere with HIF-α mRNA stability [90 Taguchi 2008],[91 
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Bruning 2011],[92 Chamboredon 2011].  It has also recently been shown that the 
protein RACK-1 can bind to HIF-α and elongin C to recruit an E3 ubiquitin protein-ligase 
complex in lieu of pVHL [93 Liu 2007].  This process is not dependent upon oxygen.  
ROSs also appear to play a role in HIF regulation, presumably by oxidizing hydroxylase-
bound Fe2+ and abrogating its ability to serve as a cofactor in hydroxylating reactions [94 
Pan 2007].  SIRT-3 was shown to help destabilize HIF-α by inhibiting ROS production [95 
Finley 2001].  It is interesting to note that ROSs contribute to stabilizing HIF, as one of 
the major behaviors regulated by HIF is oxygen conformance of the mitochondria.  
Reducing oxidative phosphorylation in conditions of low oxygen presumably help limit 
excessive ROS production which would lead to cell damage.  It is not surprising to find, 
then, that several metabolic intermediates of the citric acid cycle have also been 
reported to inhibit hydroxylase activity, including citrate, isocitrate, malate, 
oxaloacetate, pyruvate, succinate, and fumarate, [96 Kaelin 2008].  Luo et al. also found 
that pyruvate kinase isoform M2 (PKM2), the enzyme that catalyses the final step in 
glycolysis, can function as a coactivator of HIF-α [97 Luo 2011].  PKM2 can associate 
directly with HIF-1/2α and p300 to enhance their binding to HREs.  Additionally, the 
mammalian target of rapamycin (mTOR) protein has been shown to enhance HIF activity, 
and this enhancement could be inhibited by rapamycin [98 Semenza 2003],[99 Land 
2007].  Finally, very recent studies have suggested that epigenetics are involved in the 
regulation of HIF, with DNA and histone modifications altering accessibility and 
transcribability of HIF target genes [100 Tanimoto 2010],[101 Mimura 2011],[102 Xu 
2012],[103 Vanharanta 2013],[104 Nguyen 2012]. 
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1.2.6 Gradation of HIF Response 
 
The sensitivity of P4H2 to changes in oxygen concentration also imparts a graded 
responsiveness of HIF-1 to O2.  Jiang et al. exposed HeLa cells to oxygen concentrations 
ranging from 0% to 20% and measured levels of both HIF-1 subunit proteins as well as 
HIF-1 DNA binding [105 Jiang 1996b].  As expected, the HIF-1α subunit was dramatically 
responsive to oxygen concentration.  Between 20% and 6% oxygen, HIF-1α levels and 
DNA binding modestly increased as oxygen concentration decreased.  However, below 
6% oxygen both HIF-1α and HIF-1 DNA binding increased exponentially to reach 
maximal values at 0.5% oxygen.  Half-maximal responses were observed between 1.5 
and 2% oxygen.  Thus, the majority of HIF-1 activity takes place over a physiologically 
relevant range of oxygen (0 - 5%), with the largest response occurring at physiologically 
hypoxic levels (0.5 - 1.5%).  
Bracken et al. tested the graded response of HIF-1 in a similar set of experiments 
with a variety cell lines: HEK293T, HeLa, COS-1, HepG2, CACO-2, and PC12 cells [106 
Bracken 2006].  In every case, they also found an exponential increase in HIF-1α protein 
levels as oxygen was decreased from 5% to <1%.  However, though HIF-1 activity, as 
measured by reporter protein production, was also maximal below 1% oxygen, the 
response did not always match HIF-1α protein levels.  In addition to differences in 
maximal reporter protein production levels between cells types, they noted two 
categories of response.  Some cells gradually increased reporter protein production as 
oxygen decreased from 10% to <1%.  Others required an oxygen concentration of <2% 
before exhibiting a dramatic increase in reporter protein production, which much more 
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closely coincides with changes in HIF-1α levels.  This indicates that hypoxia is better 
defined by cellular response than by absolute oxygen concentration. 
 
1.2.7 Kinetics of HIF Response 
 
The rate of HIF degradation/stabilization is also important to the responsiveness 
of its activity.  Traditional immunoprecipitation assays reveal a half-life for HIF-α of 
approximately 5-8 minutes in normoxic conditions [65 Huang 1998],[107 Jaakkola 
2001],[108 Jeong 2002].  Using a firefly luciferase reporter protein fused to the HIF-1α 
gene, Moroz et al. reported a half-life of 4-6 minutes for the factor [109 Moroz 2009].  
However, though HIF-α is very unstable in normoxia, HIF-α mRNA is constitutively 
expressed and the protein is constantly produced.  Additionally the Km of P4H2 for O2 is 
just above the concentration of O2 in air.  This high value ensures that even a small 
decrease in oxygen is likely to have a significant effect on P4H2 activity [110 Hirsila 
2003].  Thus HIF-1 can be both a highly-sensitive and rapidly-responsive initiator of 
hypoxia response. 
Wang and Semenza studied the kinetics of HIF-1α protein stabilization and DNA 
binding in hepatoma cells exposed to 1% oxygen for 0-4 hours [111 Wang 1993b].  They 
found that HIF-1 activity was first detectable within 15 minutes, with 8% maximal 
activity at 30 minutes, 50% maximal activity between 1 and 2 hours, and maximal 
activity at 4 hours.  After rapid re-exposure to 20% oxygen, HIF-1 activity was reduced to 
34% within 5 minutes and was eliminated by 15 minutes.  The group also showed that 
binding of stabilized HIF-1 to DNA occurred rapidly, with 77% binding within 1 minute 
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and 100% binding within 5 minutes.  Likewise, DNA binding decay occurred with a t1/2 of 
1 minute upon reoxygenation of the cells. 
 More recently, Jewell et al. used tonometers to rapidly equilibrate suspensions 
of HeLaS3 cells to various oxygen conditions and study the time-course of HIF-1α 
accumulation and degradation [112 Jewell 2001].  Presence and DNA binding of nuclear 
HIF-1α was detected within 2 minutes of hypoxic exposure, with nuclear HIF-1α protein 
levels reaching a maximal value by 1 hour.  Within 2 minutes of reoxygenation, DNA 
binding was reduced while nuclear HIF-1α protein levels were reduced within 4-8 
minutes and undetectable by 32 minutes.  These studies point to the capability of both 
rapid onset and rapid cessation of hypoxic signaling by the HIF mechanism. 
 
1.2.8 Transcriptional Targets of HIFs 
 The primary role of HIF-mediated transcriptional regulation is to promote cell 
survival in acute hypoxia and cellular adaptation to prolonged hypoxia.  As a rapid 
response to hypoxia, HIF mediates global changes in metabolism in order to reduce 
overall cellular ATP consumption.  A traditional view of hypoxia held that lack of oxygen 
would inhibit oxidative phosphorylation, limiting the production of ATP which would be 
rapidly depleted if normal cell activities continued.  As discussed, more detailed analyses 
suggest that oxidative phosphorylation is not limited under normal physiological hypoxia, 
but reduced oxygen concentrations affect its efficiency, resulting in higher levels of 
premature electron loss from the ETC and greater ROS formation.  In order to avoid 
cellular ROS damage, HIF mediates the reduction of oxidative phosphorylation and the 
activation of glycolytic metabolism.  However, because glycolytic metabolism cannot 
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sustain the level of ATP production achieved by oxidative phosphorylation, HIF also 
mediates cell-wide reduction of ATP-intensive activities to avoid depletion. 
 HIF additionally mediates cell behaviors which function to adapt a cell to 
prolonged hypoxia or to remediate the hypoxic state.  For instance, HIF-induced 
upregulation of EPO helps to increase the number of oxygen-carrying red blood cells in 
the local vicinity.  Such hypoxia-driven behavioral response are often observed during 
embryonic development, where the local microenvironmental oxygen concentration 
helps to inform cells about their relative bodily location and direct the behavioral 
sequences that are required for normal organismal growth.  It is not surprising, then, to 
find that HIF functioning is mandatory to embryogenesis, with absence of HIF-1 function 
being embryonic lethal [113 Maltepe, 1997],[114 Iyer 1998],[115 Ryan 1998].  Hif1a-/- 
mice die at embryonic day 9 due to vascular and cardiac defect/deformity [114 Iyer 
1998],[116 Melillo 1995].  
 Because of the number of processes that are linked to cell metabolism, and 
therefore at least indirectly dependent upon oxygen, HIF has the potential for enormous 
regulatory oversight in cells.  To date, over 100 genes have been identified as direct 
targets of HIF-1/2 [117 Loboda 2010].  These genes are involved in any number of cell 
processes, including energy metabolism, transcriptional regulation, cell cycle and 
growth, viability and apoptosis, transport, signaling, migration, matrix and barrier 
function, paracrine activity, and differentiation [81 Schofield 2004],[118 Semenza 
2000],[119 Ke 2006].  A list of well-known HIF targets are presented in Table 1.2.  
Furthermore, because HIFs govern transcription of a large number of other transcription 
28 
factors, the number of genes that are indirectly regulated by HIFs is much larger.  In fact, 
by some estimates, as many as 5% of the genes in the human genome are HIF-regulated 
in hypoxic conditions [98 Semenza 2003].  In gene expression profiles performed in 
arterial endothelial cells, Manalo et al. found that the largest group of genes up-
regulated by HIF-1 included transcription factors, with cytokines/growth factors, 
receptors, and other signaling proteins also displaying significant upregulation [120 
Manalo 2005].  Genes downregulated in hypoxia are generally involved in cell growth 
and proliferation [120 Manalo 2005],[121 Goda 2003].  Using chromatin 
immunoprecipitation and comparing results to genome-wide transcript profiling, other 
groups likewise found a large number of genes to be up- and downregulated in hypoxia, 
but reported that only upregulated genes appeared to contain an HRE sequence in the 
promoter [122 Mole 2009],[123Schodel 2011].  This implies that direct transcriptional 
regulation by HIF is accomplished almost entirely by gene upregulation (in fact over 20% 
of genes upregulated in hypoxia were direct HIF targets [122 Mole 2009]), while down 
regulation is accomplished indirectly.  Indeed, of 191 genes downregulated in hypoxia in 
five different cell types, Ortiz-Barahona et al. found none of them to be directly targeted 












Table 1.2 Direct transcriptional targets of HIF-1. 
Function       Gene/Gene Product Function         Gene/Gene Product 
Glucose Adenylate kinase 3  













Pyruvate kinase M 
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1.2.9 Cell Type Variation in HIF Responses 
 
 HIF-mediated responses to hypoxia also display heterogeneity between cell 
types [125 Stroka 2001],[126 Chi 2006],[127 Gardener 2008],[128 Brachen 2006],[129 
Lendahl 2009].  Benita et al. examined hypoxia-responsive genes in 7 different cell types 
and found wide variability in HIF activity [130 Benita 2009].  Monocytes displayed 486 
genes that were differentially expressed in hypoxia while HeLa cells displayed 2119 such 
genes.  Of these genes, 159 and 555, respectively, displayed an HRE sequence in the 
promoter region.  Furthermore, only 17 genes responded to hypoxia in all of the studied 
cell types.  The group concluded that a small subset of HIF direct-target genes, generally 
involved in the shift from oxidative to glycolytic metabolism and cessation of cellular 
growth/proliferation, represent the “core” HIF response to hypoxia.  Genes that 
displayed variable responsiveness to hypoxia between cell types were less likely to 
contain an HRE sequence, suggesting that cell-type variation in gene expression is 
controlled indirectly by HIF.   
Secondary factors that are involved in HIF indirectly-regulated pathways are 
often affected by a cell’s phenotype and current physiologic context.  This helps to 
explain how cellular responses to hypoxia can vary despite similar levels of HIF mRNA 
expression in most hypoxic cells.  For instance, while most cells undergo inhibition of 
proliferation in hypoxic conditions, vascular endothelial cells are often triggered to 
divide and migrate under hypoxia as part of the angiogenic response.  Likewise, 
Bcl2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) and p53 contribute to 
HIF-regulated apoptotic cell death, while B-cell lymphoma 2 (Bcl-2) family proteins can 
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promote HIF-regulated cell survival in hypoxia [127 Gardener 2008].  Because cellular 
activity can impact the effect of HIF-signaling, it is reasonable to predict that cells whose 
primary functions involve energy-intensive activities will be more negatively impacted 
by hypoxia, while cells with low energy requirements should be tolerant of hypoxia.  
Indeed, this appears to be the case: neurons, pancreatic β-cells, and cardiomyocytes are 
all highly oxygen dependent, with their primary functions (de/re-polarization, muscle 
contraction, and insulin secretion, respectively) being severely diminished in hypoxic 
conditions.  Alternatively, articular chondrocytes have very low metabolic requirements 
and tolerate prolonged hypoxic exposure for the majority of their mature life cycle. 
 Of recent interest has been how the various HIF isoforms contribute to 
differential hypoxic responses in different cell types.  While HIF-1 is expressed in all 
metazoan cells, HIF-2 is restricted to specific cell types in vertebrates [131 Semenza 
2011a].  Furthermore while HIF-1 and HIF-2 exhibit some of the same target genes, they 
can also mediate regulation of different cell functions without overlap.  This means that 
because both HIFs recognize the same HRE sequence in target genes, HRE and PHD 
binding affinity for HIF-1 versus HIF-2 can influence which responsive cell behaviors are 
elicited in hypoxia [132 Kenneth 2008].  While HIF-1 globally regulates genes involved in 
glycolytic metabolism and complex patterns of genes affecting cell survival versus 
apoptosis decisions, HIF-2 is only expressed in certain cells of the kidney, liver, pancreas, 
lung, heart, intestine, and epithelium and does not contribute to affecting glycolysis 
[117 Loboda 2010],[133 Hu 2003].  HIF-2 is prominently expressed in the vascular 
endothelium during embryonic development and may contribute to maintenance of 
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normal vascular architecture.  It has also been shown to be the primary HIF isoform 
mediating transcriptional regulation of octamer-binding transcription factor 4 (Oct4), 
which is crucial to stem cell self-renewal, and transforming growth factor β (TGF-β) [134 
Raval 2005],[135 Covello 2006].  HIF-3 acts as an antagonist to HIF-1 and HIF-2 by 
forming a functionally inactive dimer with HIF-β [136 Makino 2001].  Elucidating the 
different expression profiles, activities, and roles of the HIF isoforms in different 
cells/tissues remains an active area of cellular research [128 Brachen 2006]. 
 
1.2.10 HIF: Implications for Identifying Hypoxia 
 
 Given the broad array of cellular behaviors that HIFs can mediate, and knowing 
that physiological hypoxia is a normal and often required condition in organismal 
growth, development, and activity, it is clear that identification of hypoxic status is of 
import to biomedical research.  However, identifying hypoxia, especially on the cellular 
level, is tricky.   Krohn et al. adroitly explain: 
 
“Hypoxia is therefore a phenomenologic concept. There is no specific 
value of O2Hb [oxyhemoglobin] concentration, % Hb saturation by 
oximetry, or tissue partial pressure, PO2 measured with electrodes, that 
results in a transition from normoxia to hypoxia…  The biologic 
consequences of hypoxia depend on duration and the needs of individual 
cells…” [137 Krohn 2008] 
 
 
Hypoxia, therefore, may be best defined in terms cell behavioral responses.  The 
following section offers a discussion of current techniques for detecting hypoxia at the 
tissue and cellular levels, highlighting advantages and disadvantages of each, and 
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proposes that a fluorescent HIF reporter system is particularly well suited for identifying 
hypoxia in 3D tissue cultures and engineered tissue constructs in vitro. 
 
1.2.10.1 Current Methods for Detecting Hypoxia  
 
 Current strategies for identifying hypoxia are typically aimed at either tissue- or 
cell-level detection.  At the tissue level, evaluation usually consists of measuring or 
analyzing some biomolecule present in the blood or interstitial fluid that is differentially 
affected in hypoxic conditions.  At the cell level, stains or markers are often used to 
detect intracellular changes indicative of hypoxia.  Hypoxia detection strategies can also 
be categorized by whether they measure environmental conditions (oxygen 
concentration) or biochemical conditions (behavioral changes). 
 
1.2.10.1.1 Indirect Measures of Hypoxia 
 
Many indirect techniques for imaging hypoxia at the tissue level have come from 
cancer research, where hypoxia in tumors has been found to be associated with poor 
outcomes.  Magnetic resonance imaging (MRI) can be used to distinguish between 
oxygenated hemoglobin and deoxyhemoglobin, giving an indication of local oxygen 
availability in the vasculature of a given tissue [138 Kim 2005],[139 Leontiev 2007].  
While this technique can be used to assess temporal changes in relative tissue 
oxygenation, it is not capable of providing quantitative information.  MRI can also be 
used to measure increases in tissue lactate, which builds up as a result of increased 
glycolytic metabolism.  Both of these approaches measure downstream consequences 
of hypoxia, which can exhibit some lag and also persist for a time even after normoxia 
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has been restored.  MRI can also be used to measure pO2 directly, using an oxygen-
sensitive reporter perfluorocarbon injected into the site of interest [140 Mason 
1993],[141 Zhao 2004].  This technique is dependent upon adequate perfluorocarbon 
perfusion of the study tissue.  However, for routine in vitro studies, use of MRI is 
impractical.  Furthermore, these techniques focus on identifying hypoxia on a tissue-
wide scale and may not have the resolution to identify hypoxia on the cellular level. 
 Various oxygen probes are also used to detect hypoxia.  Microelectrodes can 
precisely measure the local oxygen concentration down to a very small scale, and may 
offer quantitative information about the oxygen conditions at a specific location, even at 
the cellular level [142 Vaupel 1991],[143 Collingridge 1999],[144 Kim 2003],[145 Mason 
2003].  However, they require O2 for detection, meaning that as oxygen concentrations 
become very small, readings become less reliable.  Fluorescent needle type oxygen 
probes contain a fluorophore which is quenched in the presence of oxygen, eliminating 
the variability of readings at low oxygen levels [146 Jorge 2006].  However, oxygen 
probes of any kind provide only very local information about oxygen concentration and 
require a large number of evaluations to obtain meaningful spatial information about 
oxygen distribution.  Furthermore, any such probe requires placement in the tissue, 
leading to damage and inflammatory responses that can alter local tissue oxygen levels. 
 Nitroimidazoles represent a more direct method for identifying hypoxia.  
Nitroimidazoles can act as oxygen mimetics, accepting terminal electrons from the ETC.  
Their affinity for electrons is less than O2, so that under normal oxygen conditions only 
low levels of nitroimidazoles are reduced.  These molecules are only singly reduced and 
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can still be easily oxidized by O2.  However, under hypoxic conditions, without 
competition from oxygen, nitroimidazoles become doubly reduced, forming alkylating 
agents that react indiscriminately with cellular macromolecules, thus trapping 
nitroimidazole within the cell [137 Krohn 2008].  For tissue-wide analysis, the 
nitroimidazole can be radiolabeled for positron emission tomography (PET) [147 
Adamsen 2005].  Antibodies to the nitroimidazole, pimonidazole (commonly available as 
Hypoxyprobe-1), have also been prepared.  This allows for immunohistochemical 
staining and analysis of samples for the identification of hypoxia down to the cellular 
level [148 Varia 1998],[149 Olive 2000],[150 Nordsmark 2003].  A primary disadvantage 
of histological analyses is that they require the sacrifice of the tissue/construct under 
study.  Therefore, it is not possible to monitor the hypoxic status of the sample over 
time or in response to changing conditions. 
 Another approach is to predict the occurrence of hypoxia by computational 
modeling [151 Gross 2007],[152 Cheema 2008],[153 Buchwald 2009].  Models provide 
the ability to draw predictive conclusions about expected oxygen concentrations and 
gradients without the need for cell culture.  However, while modeling is a powerful tool, 
results are only as powerful as the assumptions on which the model is based, which in 
turn are guided by current knowledge of the system being modeled.  Therefore, an 
incomplete understanding of cellular processes can lead to models which do not 
accurately recapitulate observed phenomena. 
 The methods represent indirect approaches to detecting hypoxia.  In these 
techniques, indicators of hypoxia are evaluated but the immediate effector of response 
36 
to hypoxia, HIF, is not.  Alternatively, direct HIF detection may be a better determinant 
of hypoxia within a cell as it is the mediator which transitions a cell’s status from 
“normal” to “hypoxic”. 
 
1.2.10.1.2 Direct Measures of Hypoxia: HIF Detection 
  
Direct detection of HIF is perhaps a more telling indicator of whether or not a 
cell is experiencing hypoxic stress than measurements of oxygen or detection of 
metabolites involved in secondary hypoxia responses.  HIF-1 stability is highly sensitive 
to oxygen concentration with a graded and rapid response to hypoxia.  Thus, 
intracellular levels of HIF-1 both directly correspond to a cell’s immediate state of 
oxygenation and are predictive of imminent biochemical cellular responses that occur as 
HIF activity affects transcription.  Real-time polymerase chain reaction (RT-PCR) can be 
performed to quantify changes in HIF-α mRNA levels; however, as HIF-α is constitutively 
expressed in most cells, this is not a good indication of transition of a cell to a hypoxic 
state.  Alternatively, the HIF-α protein itself can be identified.  This is commonly done by 
immunohistochemical/immunofluorescent staining, which can indicate HIF localization 
in a tissue, or by Western blotting which allows for quantification by densiometry.  
These methods directly measure a cell’s hypoxic status.  However, they do suffer from a 
number of drawbacks.  First, the short half-life of HIF-α makes accurate capture and 
determination of protein levels difficult.  Secondly, basal and elevated HIF-α levels can 
vary among cell types, meaning that specific concentrations of HIF-α do not always 
correspond directly to a consistent level of transcriptional changes in a cell.  Most 
importantly, however, is that both immunostaining and Western blotting protocols 
37 
require the sacrifice of the tissue of interest.  This means that repeated analysis of 
hypoxic status within the same sample cannot be performed.  Thus by these methods, it 
is difficult to develop a temporal profile of the hypoxic response within a cell. 
 An alternative approach to HIF protein detection is the use of a reporter system.  
Several groups have detailed the use of an engineered vector containing repeats of the 
HRE enhancer and a minimal promoter to allow for hypoxia-induced expression of a 
fused gene.  Given the appropriate reporter protein, this approach conveniently allows 
for the kinetics and magnitude of HIF-mediated effects on transcription to be observed.  
Furthermore, if the reporter protein is non-toxic to the cell and is easily detected, 
repeated observations of the same sample can be made.  
 The majority HIF reporter vectors detailed in the literature have been 
constructed as potential targeted gene-therapies for cancer treatment or diagnostic 
tools for the identification of hypoxia in tumors.  Shibata et al. prepared a vector 
containing five HRE repeats from the human VEGF gene coupled to a minimal 
cytomegaloviral (CMV) promoter with luciferase as a reporter gene [154 Shibata 2000].  
They reported a 500-fold increase in luciferase expression in response to hypoxia in 
transfected cells.  This type of vector was suggested as a means to selectively express a 
therapeutic agent (in lieu of the luciferase reporter gene) in tumors which are generally 
hypoxic compared to normal tissues [154 Shibata 2000],[155 Payen 2001].  Indeed, a 
similar vector containing a suicide gene (herpes simplex virus thymidine kinase) under 
HRE control was used to induce tumor regression in mice [156 Koshikawa 2000].  
Similarly, Harada et al. used a HRE-luciferase reporter system to observe changes in the 
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number of hypoxic cells within a tumor to evaluate the effectiveness of cancer drugs 
[157 Harada 2005]. 
 The recent characterization and marketing of a number of genes whose 
products are stable fluorescent proteins has also allowed for the construction of 
imagable hypoxia reporter systems.  Vordermark et al. reported the suitability of green 
fluorescent protein (GFP) as a reporter gene product for identifying HIF activity at 
oxygen concentrations as low as 0.02% [158 Vordermark 2001].  Serganova et al. 
transfected C6 glioma cells with an HRE-GFP reporter vector and observed green 
fluorescence, indicating HIF-mediated transcriptional activity, in tumor masses 
comprised of the cells [159 Serganova 2004].  They noted the particular usefulness of 
this approach for determining dynamics and spatial heterogeneity of HIF-1-specific 
transcriptional activity [159 Serganova 2004]. 
A fluorescent reporter of HIF activity appears to be a relevant and useful tool for 
determining whether or not a cell is hypoxic and investigating different 
microenvironmental conditions that can result in HIF-induced changes in cell behavior.   
Such a system identifies cellular hypoxia in terms of cell behavior and offers a good 
estimate of the expression of other direct HIF targets.  The method also avoids a 
number of the problems inherent in other hypoxia detection techniques, such as the 
need to sacrifice the study sample.  However, very little use of such a system outside of 
tumor hypoxia has been reported.  As discussed, low oxygen conditions can be common 
in the human body and can be necessary to drive normal and appropriate biological 
processes.  As researchers make increasing efforts to simulate in vivo conditions in their 
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in vitro studies, there is an apparent need to understand how environmental signals, like 
oxygen tension, in a cell’s physiological environment contribute to affecting its function.  
Use of a fluorescent reporter system to identify HIF activity and correlate it to other 
relevant changes in cell behavior should begin to fulfill this need. 
 
1.3 Regulating Hypoxia to Affect Cell Behaviors in Transplantation Therapies 
 
The loss or failure of tissues and organs due to damage and disease is one of the 
most prevalant and expensive problems encountered in medicine today [160 Laschke 
2006]. Since it was officially defined by the National Science foundation in 1987, the 
field of tissue engineering has offered the promise of addressing this issue through 
development of functional replacement tissues that are transplanted into the recipient 
[161 Langer 1993].  With the subsequent discovery and utilization of embryonic and 
adult stem cells, tissue engineering has slowly become encompassed under the 
umbrella of “regenerative medicine”, which, as defined by Mason and Dunnill, 
“…replaces or regenerates human cells, tissues or organs to restore or establish normal 
function” [162 Mason 2008].  By this definition, any cell-transplantation therapy 
qualifies as regenerative medicine.  Regenerative medicine combines the use of cells, 
materials, and bio-physical/chemical stimuli in a rational effort to produce functional 
tissues that are closely analogous to native tissues for the treatment of defects or 
disease.  A key feature of regenerative medicine is the harnessing of innate properties 
and capabilities of cells that are difficult, if not impossible, to reproduce artificially.  The 
cellular genome contains all of the inherent instructions required to run the myriad 
biological processes that together result in a living organism.  Through evolution, these 
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have developed into a highly regulated and enormously complicated pattern of 
conserved and emergent cell behaviors that allow for survival and reciprocal interaction 
with the world.  Tissue engineers, then, have the difficult task of applying, in an 
intelligent manner, what information has been learned about these preprogrammed cell 
functions in order to drive desired cell behaviors while restricting undesired ones in an 
effort to develop therapies for tissue restoration. 
 It has become increasingly noted that for cell transplantation and tissue 
engineering endeavors to succeed, the in vitro conditions in which tissue 
growth/fabrication takes place will need to closely mimic the native physiological 
environment.  Differences between the conditions that cells encounter in culture and in 
the body can lead to discrepancies between in vitro and in vivo results.  One of the most 
non-physiological conditions encountered by cells in routine cell culture is elevated 
exposure to oxygen.  In atmospheric culture conditions, cells are exposed to nearly 21% 
O2, whereas oxygenation of a typical tissue in the body is much lower.  Therefore, 
investigators using standard culture conditions may not observe the same responses 
from cells as might typically be seen in vivo.  As more research is performed at 
physionormal oxygen concentrations, it will be important to monitor the hypoxic status 
of cells in culture and observe the effects of reduced oxygen on cell behavior.  
Furthermore, tissue engineering is often concerned with the production of 3D tissues, 
which differ widely from the monolayers typical of standard culture.  Because oxygen 
delivery occurs by diffusion from the media in vitro, oxygen gradients can easily form in 
3D tissues, thus exposing cells to heterogeneous oxygen conditions.  Because of this, 
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oxygen tension in many tissue engineered constructs may exert a significant, and 
potentially more complicated, effect on cell behavior than is typically considered. 
 A fluorescent hypoxia reporter system, described in the present work, provides a 
means for evaluating hypoxia and its effects in different cell systems.  Though its role in 
signaling has become much better understood, “hypoxia” is still often viewed with a 
negative connotation, as it can lead to aberrant cell behavior and cell death.  However, 
many beneficial behaviors, such as vascularization and wound healing, can also be 
triggered by hypoxia.  Thus, hypoxia’s role in cell transplantation and tissue engineering 
is phenomenological and context dependent.  In the present work, it is hypothesized 
that for different 3D tissue systems, tissue dimensions and external oxygen 
concentration (both controllable culture parameters in vitro) contribute to the hypoxic 
status experienced by cells within the culture, and can work to promote desirable, 
hypoxia-induced behaviors or, alternatively, to inhibit cell function (Figure 1.4).  This 
dual nature of hypoxia in cell-based, tissue engineering therapies, as well as the 
versatility of a fluorescent HIF reporter for use in its study, is highlighted in two systems 
which were the subject of the present work: islet-like β-cell clusters, and ADSC 
spheroids.  In β-cell clusters, beneficial cell behavior is achieved by avoiding hypoxia, 
while in ADSC spheroids, hypoxia promotes the desired behavior.  The importance of 
these systems as transplantation therapies as well as the role of hypoxia in each is 
discussed in the following sections. 
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Figure 1.4 Schematic of development of hypoxia in 3D 
cultures.  The extent of hypoxia within a cell aggregate 
should be affected by aggregate size and external oxygen 
concentration.  To achieve the desired cell behavior, it may 
be possible to vary these parameters to optimize hypoxic 
status throughout the aggregate. 
 
 
1.3.1 Encapsulated β-cells as a Treatment for Type I Diabetes Mellitus 
 
Type 1 diabetes mellitus (T1DM) is a chronic inflammatory disease of the 
pancreas resulting in the body’s inability to produce insulin.  β-cells, the cells responsible 
for insulin production and secretion, reside within specialized tissue clusters called the 
islets of Langerhans found within the pancreas.  In T1DM, the β-cells are destroyed, 
presumably through a dysfunctional autoimmune process.  Without the insulin 
produced by β-cells, the body tissues are unable to take in and utilize glucose, the 
primary energy product of metabolism and the body’s main energy source.  If untreated, 
T1DM is fatal.   
There are currently several treatment options for T1DM, offering the potential to 
improve patient prognosis considerably.  Exogenous insulin administration via injection 
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is the most prevalent such option.  By constantly monitoring blood glucose levels and 
administering insulin when needed, diabetic patient quality of life and life expectancy 
can be much improved.  However, besides the discomfort of repeated blood drawl and 
hypodermic injection, this method also inadequately replicates what the body does 
naturally.  In the body, islets are well perfused with blood and β-cells can continually 
monitor blood glucose levels and respond by secreting the appropriate amount of 
insulin.  This continual monitor/secrete system is called responsive release, and it 
ensures that at any given moment the amount of insulin and glucose in the blood are 
appropriately balanced to achieve the correct physiological function.  Exogenous 
supplementation of insulin, however, occurs in doses.  Doses are administered 
periodically in amounts estimated to adequately process the glucose load of a meal over 
a given time period.  Such periodic administration means that insulin concentration is 
not necessarily matched to glucose concentration at all times.  Thus, exogenous insulin 
supplementation often fails to prevent the chronic, systemic complications of T1DM, 
such as retinopathy, glaucoma, neuropathy, and hypertension, over time. 
In the normal physiological state, the body naturally secretes insulin in a 
responsive manner dependent upon blood glucose concentration at a given moment.  It 
stands to reason, then, that an ideal method for treating T1DM would do the same.  
Because β-cells are specifically specialized to perform this task, transplantation of 
functional pancreatic tissue to replace compromised islets offers an appealing 
treatment approach.  Transplantation was first attempted as a treatment for severe 
T1DM in 1966, with allotransplantation of a pancreas, duodenum, and kidney 
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concurrently [163 Kelly 1967].  This and other subsequent early attempts offered poor 
outcomes due to complications from the invasive surgery and the requirement of 
immunosuppressive drugs to prevent organ rejection.  Later transplantation attempts 
made use of the fact that islets represent only a small percentage of the total pancreatic 
mass but are sufficient for remediating T1DM.  Islets were isolated and purified from 
donor pancreata and transplanted into recipients, greatly reducing surgical invasiveness 
but still requiring a life-long immunosuppressant regimen to prevent rejection.  Besides 
issues with long-term immunosuppressant drug use, transplantation procedures also 
suffer from donor limitations.  The islets from as many as three donors are required to 
satisfy the needs of single recipient.  Thus, although positive outcomes have been 
achieved by islet transplantation, methods to improve the procedure and overcome 
limited tissue supply continue to be explored. 
Encapsulation has been considered as means of overcoming the main 
shortcomings of islet transplantation.  Encapsulation separates the transplanted tissues 
from the cells of the immune system and offers two benefits.  First, possibility of 
immune rejection is greatly reduced so that immunosuppressive drugs are not required.  
Secondly, the avoidance of an immune response makes utilization of xenotypic tissue 
sources a potential way to overcome limited donor supply.  Lim and Sun first evaluated 
the potential of this technique by encapsulating rat islets in semipermeable, cross-linked 
alginate [164 Lim 1980].  They then examined viability and function of the islets in vitro 
and in chemically induced diabetic rats. They found that encapsulated islets exhibited 
glucose-stimulated insulin secretion (GSIS) similar to unencapsulated islets and could 
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restore normoglycemia in the mice for at least 20 days, compared to six day survival of 
mice receiving unencapsulated islets.  More recent trials have shown 
xenotransplantation proof of concept, with alginate-encapsulated pig islets functioning 
to remediate hyperglycemia in diabetic monkeys [165 Dufrane 2006a] and dogs [166 
Abalovich 2009] for several months without immune rejection.  Elliott et al. even 
reported viability of alginate-encapsulated pig islets 9.5 years after transplantation into 
a human (function was lost after 14 months) [167 Elliott 2007], thought a second group 
was unable to duplicate the result [168 Tuch 2009].  However, limited duration of 
viability/function of encapsulated islets has largely restricted the overall success of 
transplantation therapies.  Capsule material and nutrient delivery (especially oxygen) 
are the two major parameters that appear to most affect encapsulated islet 
performance. 
 
1.3.1.1 Poly(Ethylene Glycol) as a Favorable Material for β-Cell Encapsulation 
 
A majority of current encapsulation trials utilize hydrogels as the semipermeable 
matrix which separates β-cells from immune cells.  Hydrogels are appealing for their 
ability to hold many times their volume in water, which provides a large aqueous 
environment for the encapsulated cells.  Though alginate-based gels are traditionally the 
most utilized, poly(ethylene glycol) (PEG) hydrogels represent a promising alternative.  A 
shortcoming of alginates has been their propensity to become fibrotically overgrown if 
not adequately purified [169 Langlois 2009] and their batch-to-batch variability making 
comparisons between studies difficult.  Recent direct comparisons have shown that, in 
these two respects, PEG yields superior performance [170 Liu 2010].  In addition to 
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being highly biocompatible, PEG is also easily functionalized and non-degrading when 
covalently crosslinked.  PEG hydrogels have already been shown to support a number of 
cell types including chondrocytes [171 Bryant 2002],[172 Rice 2004], osteoblasts [173 
Burdick 2002], valvular interstitial cells [174 Benton 2009], and mesenchymal stem cells 
[175 Nuttelman, 2004].  PEG network permeability, a function of mesh size, is also easily 
manipulated by varying macromer concentration and size in the photoactive solution 
[176 Cruise 1998].  Lin-Gibson et al. provided a method for photopolymerizing PEG 
dimethacrylates (PEGDM) that had been prepared by microwave methacrylation of PEG 
[177 Lin-Gibson 2004].  Using this method, Weber et al. showed that polymer mesh size 
was easily controlled by appropriate selection of initial macromer size [178 Weber 2008] 
and that such hydrogels were suitable for sustaining β-cells [179 Weber 2006].  Bryant 
et al. showed that neither the photoinitiator nor time of UV exposure used in the 
photopolymerization process was toxic to the cells [180 Bryant 2000]. 
 
 1.3.1.2 Hypoxia in Islet Encapsulation 
 
Loss of function and/or viability is often observed in a significant percentage of 
cells following tissue isolation and encapsulation procedures.  This has been especially 
noted of islets of Langerhans, transplanted as a treatment for T1DM [181 De Vos 
1997],[182 Suzuki 1998],[183 De Vos 1999].  While a variety of factors have been 
investigated, hypoxia has increasingly been implicated as the primary cause for this 
observed device failure, with insulin secretion by the pancreatic β-cells being 
particularly sensitive to changes in oxygen concentration [184 Dionne 1989],[185 
Dionne 1993],[186 de Groot 2003].  Low oxygen tension in explanted islets can be 
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directly attributed to their removal from the rich vasculature of the pancreas.  
Encapsulation exacerbates this problem in two ways: 1) by prohibiting islet 
revascularization and 2) by adding an additional barrier to oxygen transport.  Outcomes 
in unencapsulated islet transplants have shown that diffusion of oxygen and nutrients to 
islets in well-perfused sites of the body prior to revascularization can be sufficient to 
maintain viability and function [187 Shapiro 2000],[188 Shapiro 2006].  A capsule, 
however, may hinder diffusion of oxygen to encapsulated tissues because of 
permeability limitations and increased diffusional distance [189 Schrezenmeir 1994].  
However, besides material and geometric considerations of capsule design, a variety of 
factors such as islet size [190 Lehmann 2007],[191 Cavallari 2007], rate of oxygen 
consumption [192 Sweet 2002],[193 Wang 2005], and site of implantation [194 Dufrane 
2006b] all play a part in determining how much oxygen may be available to any 
particular cell.   
Oxygen insufficiency is known to inhibit β-cell function by decoupling glucose 
sensing from insulin exocytosis [195 Zehetner 2008],[196 Cantley 2009],[197 Puri 2009].  
Studies characterizing how size, encapsulation material, and external oxygen conditions 
affect the hypoxic status of islets as well as how techniques such as re-aggregation and 
hypoxic preconditioning contribute to hypoxic tolerance (if at all) are obviously 
important to optimizing implant function.  However, direct characterization of hypoxia, 
in terms of HIF activity, in β-cells is scarcely reported.  In the present work, use of a 
fluorescent HIF reporter was shown to facilitate such investigations, allowing for the 
determination of temporal and spatial profiles of hypoxia in 3D, islet-like clusters and 
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observation of how cluster size and external oxygen concentration contribute to 
hypoxia-mediated effects on cell function. 
 
1.3.2 ADSC Spheroids as a Cell-Based Method to Drive Angiogenesis 
 
 Despite its promise, tissue engineering has offered relatively few clinical 
successes to date [198 Griffith 2002],[199 Ikada 2006].   Lack of vascularity has 
consistently been cited as the largest obstacle to the development of clinically relevant 
engineered tissues over the past several years [160 Laschke 2006],[200 Rauwkema 
2008],[201 Lovett 2009],[202 Santos 2010],[203 Novosel 2011],[204 Horch 2012],[205 
Laschke 2012].   Most cells in the body reside within 100-200μm of a blood vessel, a 
distance which corresponds closely the theoretical limit of oxygen diffusion in a tissue 
[206 Folkman 1973],[207 Colton 1995].  For engineered tissues, which are avascular, this 
diffusional restraint limits the size of tissues that can be effectively transplanted.  
Following transplantation, local inflammation and healing processes at the implant site 
resulting from the surgical procedure can help to induce infiltration of host vessels into 
the implant.  However, the rate of vessel progression is slow and interior cells of the 
implant often do not survive long enough to be vascularized.  Several strategies for 
enhancing vascularization of engineered tissues have been described, including 
administration of pro-angiogenic growth factors, cell co-culture, and pre-vascularization.  
These strategies either attempt to promote angiogenesis, the sprouting of vascular 
branches from existing vasculature, or vasculogenesis, the de novo formation of 
microvessel networks from disorganized precursor cells.   
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Growth factors are known to be potent mediators of angiogenesis and 
vasculogenesis in vivo.  VEGF is the most powerful stimulator of angiogenesis, often 
working in concert with basic fibroblast growth factor (bFGF) [208 Carmeliet 2011].  
When triggered by these growth factors, endothelial cells in existing vessel walls secrete 
matrix metalloproteinases (MMPs), branch off from the vessel, and begin to migrate in 
the direction of the growth factor source.  Endothelial cells directly behind these 
migrating cells begin to proliferate rapidly, extending a new capillary sprout toward the 
tissue of need.  Subsequent vessel maturation is important to reducing capillary 
leakiness and preventing vessel regression.  Platelet-derived growth factor (PDGF), TGF-
β, and angiopoietin 1 (Ang-1) are involved in vessel stabilization and maturation by 
reducing MMP secretion, stimulating matrix production, and recruiting supporting cells 
such as smooth muscle cells and pericytes [200 Raukema 2008],[209 Carmeliet 
2000],[210 Hirschi 2002]. 
In regenerative medicine applications, administration of angiogenic factors can 
help to stimulate blood vessel growth and promote more rapid vascularization of tissue 
implants.  For this purpose, recombinant VEGF is often applied.  VEGF can be 
administered by direction injection; however, high dose requirements due to VEGF 
instability and negative systemic side-effects, including ectopic blood vessel 
development and excessive capillary leak, make this delivery technique unfavorable 
[160 Laschke 2006].  An alternative strategy has been to localize VEGF to the implant 
site by controlling its release from the implant itself, often a biomaterial scaffold that 
serves as the matrix component of an engineered tissue.  Many demonstrations of 
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material-based constructs for VEGF delivery are reported in the literature, displaying a 
wide variety of release profiles and mechanisms [211 Zisch 2003],[212 Sokolsky-Papkov 
2007],[213 Übersax 2009],[214 Fu 2010].  However, material-based delivery systems do 
face a number of hurdles.  First, they require both a prior knowledge of the appropriate 
delivery dosage/duration and the ability to achieve this release profile from a material 
construct.  Also, the maximal cumulative dose is predefined by the loading process 
during fabrication and cannot be augmented after implantation.  Furthermore, few 
systems are capable of responding to cellular and other microenvironmental cues that 
would modulate delivery to match physiological need.  Finally, the process of 
angiogenesis is driven by concurrent action of multiple factors each displaying different 
availability profiles which change over time; however, the appropriate relative profiles 
of many growth factors are not fully characterized in many cases, and most material-
based growth factor delivery systems have difficulty incorporating and delivering 
multiple factors differentially. 
 
1.3.2.1 Cell-Based Delivery for Therapeutic Angiogenesis in Tissue Engineering 
 
A more recent technique has been to use cells as a growth factor source, an 
approach termed cell-based delivery.  In cell-based delivery, a particular cell type is 
chosen for incorporation into the engineered tissue to promote tissue angiogenesis, 
either natively or by some inducing stimulus.  Cell-based delivery techniques are 
attractive, as researchers are able to take advantage of natural biological mechanisms 
that cells already possess.  This approach offers three key benefits [200 Rauwkema 
2008].  First, unlike most biomaterials, cells can participate in innate biological signaling 
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processes that regulate angiogenic factor secretion to maintain factor concentrations in 
the physiological range and adapt them to meet the requirements of different stages of 
vessel formation.  Secondly, growth factors secreted from cells often interact with the 
extracellular matrix to form three dimensional microgradients which contribute to 
directing capillary arrangement [215 Helm 2005].  Finally, cells may have the capability 
to produce and secrete a variety of different angiogenic factors, in physiological profiles, 
that act together to direct several stages of vessel migration, stabilization, and 
maturation [205 Laschke 2012]. 
For cell-based delivery to be effective, a cell source must be chosen that is 
capable of producing the factors of interest and providing the appropriate signals within 
the implant microenvironment.  The recently-characterized ADSCs represent a very 
promising cell population for the promotion of angiogenesis.  ADSCs are readily isolated 
from lipoaspirates which can be collected through a minimally invasive procedure.  The 
stem cell yield from adipose tissue is large, approximately 500 times greater than from 
bone marrow, where similar stromal cell populations were first identified [216 Mizuno 
2009].  Ease of culture and rapid expansion make ADSCs ideal for autologous use.  
ADSCs have also been shown to be capable of secreting a number of factors of relevance 
to angiogenesis in regenerative medicine, including VEGF; bFGF; hepatocyte growth 
factor (HGF); basic nerve growth factor (bNGF); angiogenin; Ang-1; insulin-like growth 
factor 1 (IGF-1); interleukins (IL)-6, -7, -8, -11, and -17; monocyte chemoattractant 
protein (MCP)-1 and -2; granulocyte/monocyte-, granulocyte-, and macrophage colony 
stimulating factors (CSF); tumor necrosis factor α  (TNF-α), and stromal cell-derived 
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factor 1 (SDF-1) [217 Kilroy 2007],[218 Hong 2010],[219 Rasmussen 2011].  Furthermore, 
ADSCs have shown the potential to differentiate into a variety of mature lineages of 
mesodermal and non-mesodermal origin, including adipogenic, chondrogenic, 
osteogenic, skeletal muscle, smooth muscle, cardiac muscle, epithelial, hepatocytic, 
pancreatic, and hematopoietic support cells [216 Mizuno 2009].  Of particular relevance 
are studies indicating that ADSCs can differentiate directly into endothelial precursor 
and endothelial cells [220 Planat-Benard 2004],[221 Miranville 2004],[222 Cao 
2005],[223 Colazzo 2010],[224 Keerl 2010],[225 Shi 2012]. 
In recent years, ADSCs have been shown to contribute to improved tissue repair 
in dermal wounds [226 Kim, W.S. 2007],[227 Lu 2008],[228 Kim 2009],[229 Nambu 
2009], mouse ischemic hindlimbs [221 Miranville 2004],[222 Cao 2005],[230Nakagami 
2005],[231 Moon 2006],[232 Kim, Y. 2007], and myocardial infarcts [233 Miyahara 
2006],[234 Valina 2007],[235 Cai 2009],[236 Schenke-Layland 2009],[237 Wang 2009].  
Usually, the cells are directly injected into the deficient tissue as a dispersion, or a 
seeded into a tissue scaffold for implantation.  The restorative effects of ADSCs have 
mostly been attributed to their enhancement of angiogenesis, which appears to be 
accomplished through one or more of the following mechanisms.  First, current 
evidence supports a primary paracrine activity of ADSCs, with secretion of pro-
angiogenic and anti-apoptotic growth factors contributing to enhanced tissue survival 
and increased capillary density.  (VEGF and IGF-1, for instance, have been shown to 
function in both roles [219 Rasmussen 2011].)  ADSCs also secrete factors which can 
recruit circulating stem and endothelial precursor cells, as well as various support cells 
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such as fibroblasts and pericytes [238 Takahashi 1999],[239 Crosby 2000],[240 Ceradini 
2005],[241 Nakao 2010].  In particular, SDF-1, appears to function in stem cell homing 
[242 Askari 2003],[243 Ceradini 2004].  Finally, as mentioned, ADSCs can differentiate 
into endothelial cells to directly integrate into developing vasculature.  ADSCs also share 
many common characteristics with pericytes, cells which support the vascular 
endothelium and have been shown to contribute to superior angiogenesis and vessel 
stabilization when co-cultured with endothelial cells [244 Traktuev 2008],[245 Traktuev 
2009].  Taken together, these properties suggest that ADSCs are capable of modulating 
the stem cell niche to create a local microenvironment that is highly primed to promote 
angiogenesis [246 Gimble 2007].  
 
1.3.2.2 Hypoxia and the Angiogenic Potential of ADSCs 
 
In order to fully take advantage of the angiogenic potential of ADSCs for 
regenerative medicine, researchers will need to develop techniques to control and 
possibly amplify their pro-angiogenic behaviors.  To this end, a better understanding of 
the stimuli that encourage these behaviors will be advantageous.  In the body, ADSCs 
reside in a perivasacular niche with oxygen concentrations ranging from 2-8% O2, an 
environment that has been described as locally hypoxic [247 Matsumoto 2005],[248 
Pasarica 2009],[249 Mohyeldin 2010].  This concentration encompasses the range over 
which HIFs are exponentially stabilized, suggesting that HIF activity plays an important 
part in regulating typical ADSC functions.  Indeed, hypoxia appears to be one of the 
primary motivating factors promoting ADSC paracrine activity and affecting differential 
potential.  Hypoxic culture of ADSCs has been reported to upregulate expression of 
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VEGF, bFGF, IGF-1, and HGF in vitro [219 Rasmussen 2011],[250 Rehman 2004],[251 
Rosová 2008], [252 Lee 2009],[253 Liu 2013].  In particular, the VEGF gene is known to 
contain HRE repeats in its promoter region, making it a direct target of HIF-1 [254 Levy 
1995],[255 Liu 1995],[256 Forsythe 1996].  In animal studies, hypoxic preconditioning of 
ADSCs resulted in superior survival, healing, and vascularity of ischemic skin flaps and 
myocardial infarcts in mice [257 Tang 2009],[258 Yue 2013].  Hypoxia has also been 
suggested to contribute to an increase in stem cell survival and to the secretion of pro-
survival factors from stem cells [259 Chacko 2010].  However, despite the fact that the 
potent angiogenic properties of ADSCs are largely regulated by hypoxia over 
physionormal oxygen tensions, relatively little work has focused on developing a better 
understanding of how cellular hypoxia in encountered by ADSC cultures.  Furthermore, 
Abdollahi et al. have recently concluded that “…further study is needed to optimize the 
use of hypoxia as a stimulus for various stem cell functions, including its potential role in 
therapeutic angiogenesis” [260 Abdollahi 2011]. 
Realization that oxygen is one of the key regulators of stem cell function has a 
profound significance on how current cell-based and tissue engineering applications 
using ADSCs can be further improved [261 Zachar 2011].  While upregulation of 
angiogenic growth factors by genetic engineering has been shown to enhance the 
therapeutic outcomes with stem cells [262 Geiger 2007], hypoxia can be used to a 
similar effect while eliciting a more global and complex cell response and avoiding 
potential concerns such as oncogene formation [263 Baraniak 2010].  As discussed 
previously, oxygen diffusion in a 3D tissue is known to affect oxygen tension.  Therefore, 
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in the present work, it is suggested that 3D and hypoxic culture can be used to illicit 
upregulation of angiogenic behavior in ADSCs.  In addition to the potential paracrine 
effects, 3D culture has been shown to enhance survival of cells within a spheroid 
through contact-dependent signaling and upregulation of pro-survival factors [264 
Shweiki 1995],[265 Bates 200],[266 Gaedtke 2007],[267 Bhang 2012a].  Furthermore, 3D 
culturing may serve to precondition the cells for hypoxic conditions encountered at the 
ischemic implant site [268 Saleh 2011],[269 Baraniak 2012].  Application of a fluorescent 
HIF reporter system allows for a unique characterization of hypoxia within 3D ADSC 
cultures which should serve as a supplement to the few investigations of hypoxia in 
ADSC spheroids.  Furthermore, it is hypothesized that spheroid size and external oxygen 
concentration can be adjusted to affect hypoxic status of cells throughout a culture, and 
thus control the output of angiogenic factors.  This hypothesis is investigated in the 
current work.  Using culture size to control hypoxia for tissue engineering has not been 
previously reported in the literature and has implications for optimizing tissue designs 
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A common obstacle to the survival of encapsulated tissue is oxygen insufficiency.  
This appears particularly true of encapsulated pancreatic β-cells.  Our work investigates 
a fluorescent hypoxia detection system for early recognition of hypoxic stress in 
encapsulated pancreatic tissue.  Murine insulinoma (MIN6) cells were engineered to 
produce a red fluorescent protein under the control of hypoxia-inducible-factor-1.  
Aggregates of these cells were encapsulated in poly(ethylene glycol) hydrogels at 
densities of 200,000, 600,000, and 1 million cells per capsule then incubated in either a 
1% or 20% oxygen environment.  Cell function was evaluated by daily measurement of 
glucose-stimulated insulin secretion.  Encapsulated cells were also fluorescently imaged 
periodically over 72 hours for expression of the marker signal.  Results indicate that 
oxygen insufficiency severely impacts insulin release from MIN6 cells, and that large 
aggregates are especially vulnerable to oxygen limitations.  Our marker was found to be 
successfully indicative of hypoxia and could be used as a predictor of subsequent insulin 
release.  Further work will be required to fully characterize signal dynamics and to 
evaluate in vivo efficacy.  The method presented here represents a unique and valuable 
approach to detecting hypoxic stress in living tissues which may prove useful to a variety 




Loss of function and/or viability is often observed in a significant percentage of 
cells following tissue isolation and encapsulation procedures.  This has been especially 
noted of islets of Langerhans, transplanted as a treatment for T1DM [181 de Vos 
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1997],[182 Suzuki 1998],[183 de Vos 1999].  While a variety of factors have been 
investigated, hypoxia has increasingly been implicated as the primary cause for this 
observed device failure, with insulin secretion by the pancreatic β-cells being 
particularly sensitive to changes in oxygen concentration [184 Dionne 1989], [185 
Dionne 1993],[186 de Groot 2003]. 
Low oxygen tension in explanted islets can be directly attributed to their removal 
from the rich vasculature of the pancreas.  Encapsulation exacerbates this problem in 
two ways: 1) by prohibiting islet revascularization and 2) by adding an additional barrier 
to oxygen transport.  Outcomes in unencapsulated islet transplants have shown that 
diffusion of oxygen and nutrients to islets in well perfused sites of the body prior to 
revascularization can be sufficient to maintain viability and function [187 Shapiro 
2000],[188 Shapiro 2006].  A capsule, however, may hinder diffusion of oxygen to 
encapsulated tissues by permeability limitations and an increased diffusional distance 
[189 Schrezenmeir 1994].  For many commonly used materials, oxygen can easily 
permeate and diffuse within the capsule.  Weber, et al. [178 Weber 2009], for instance, 
have shown that the diffusion coefficients of small molecules within a poly(ethylene 
glycol) (PEG) hydrogel polymerized from 10 kDa macromers approach their values for 
diffusion in water.  This implies that in terms of oxygenation, combined effects of 
capsule geometry and material may largely influence device success.  However, beyond 
material and geometric considerations, a variety of factors such as islet size [190 
Lehmann 2007],[191 Cavallari 2007], rate of oxygen consumption [192 Sweet 2002],[193 
Wang 2005], and site of implantation [194 Dufrane 2006b] all play a part in determining 
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how much oxygen may be available to any particular cell.  As such, a method for quickly 
detecting hypoxia in individual living cells would provide obvious benefits to the field of 
cell encapsulation. 
Our work reports the development of such a detection system.  HIF-1, a 
heteromeric dimer, has previously been identified as central to cellular hypoxia 
response [271 Semenza 2001].  In particular, presence of the HIF-1α subunit, necessary 
for HIF-1 activity, has been shown to increase exponentially in cells exposed to oxygen 
levels lower than 6% [105 Jiang 1996b].  We have developed a transfer vector capable of 
inserting a gene coding for production of a red fluorescent protein under the control of 
HIF-1.  In response to diminished oxygen availability, HIF-1α is upregulated, dimerizes 
with HIF-1β, and attaches to HREs in the genome, initiating transcription of native 
hypoxia response genes as well as the inserted red fluorescent protein gene.  Signal can 
be observed in living cells under a fluorescent microscope.   
To better characterize this marker, we have employed it in PEG-encapsulated 
murine β-cells.  Covalently crosslinked PEG networks have been shown to provide a 
suitable environment for β-cell survival [179 Weber 2006].  Among their favorable 
characteristics, PEG hydrogels are highly biocompatible, non-degrading, and readily 
functionalized.  Within the hydrogels, hypoxia signal expression and cell function, as 
defined by GSIS, were compared in normoxic and hypoxic conditions.  As a rapid 
indicator of hypoxia in living cells, we believe this detection system could prove useful 
not only in cell encapsulation but also in other fields in which hypoxia plays an 
important role, such as the directionalization of stem cell differentiation. 
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PEG (linear, Mn = 10,000 g mol
-1) and 1-Hydroxycyclohexyl phenyl ketone (99%) 
(Irgacure 184) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used as 
received.  Methacrylic anhydride (94%) and reagent A.C.S. grade dichloromethane (≥ 
99.5%), and anhydrous diethyl ether (≥ 99.5%) were also purchased from Sigma-Aldrich 
and used as received. 
 
2.3.2 PEGDM Synthesis and Functional PEGDM Solution Preparation 
 
Polymer was prepared in a manner similar to that described by Lin-Gibson et al. 
[177 Lin-Gibson 2004].  Methacrylic anhydride and PEG were combined in a scintillation 
bottle at a molar ratio of 10:1 by addition of 0.308g of methacrylic anhydride to 2.0g of 
PEG.  PEG was evenly melted by irradiating the bottle in a standard domestic microwave 
(1050 W) for 2 minutes, vortexing, then irradiating for another 5 minutes.  This process 
allowed for covalent addition of a methacrylate group to each PEG chain end forming 
PEGDM.  The heated solution was allowed to cool briefly before being re-dissolved in 
excess dichloromethane (~6 mL).  PEGDM was precipitated out of solution in cold 
anhydrous diethyl ether and collected by vacuum filtration.  After drying, PEGDM was 
dissolved in deionized water and transferred into cellulose ester dialysis tubing with a 
molecular weight cut-off of 1,000 Da (Spectra/Por Dialysis Membrane, Spectrum 
Laboratories, Los Angeles, California, USA).  The solution was dialyzed against deionized 
water for 5 days to purify the product.  Water was replaced every 24 hours.  After 
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purification, the PEGDM solution was transferred into an appropriate container and 
placed in a freezer at -80°C overnight.  The frozen solution was then lyophilized on a 
freeze-drier (Freezone 2.5, Labconco, Kansas City, MO, USA) for 4 days to obtain the 
final powder form.  To prepare the photoactive PEGDM solution, PEGDM was dissolved 
in Hank’s Balanced Salt Solution (HBSS, Invitrogen, Carlsbad, CA, USA) to form a 10 wt% 
solution.  Irgacure 184 was added at 0.025 wt% as a photoinitiator.  The final solution 
was sterilized by filtration through a 0.2 μm syringe filter and stored in the dark.  
Crosslinking was achieved by exposure of the desired volume of photoactive PEGDM 
solution to long wavelength UV light (352 nm).  Upon exposure, degradation of Irgacure 
184 results in production of free radicals which attack the vinyl carbon-carbon double 
bonds of the methacrylate end groups resulting in covalent crosslinking of PEG chains 
and formation of the hydrogel. 
In their work, Lin-Gibson et al. noted near stoichiometric conversion of PEG (Mn 
= 1,000 and 4,000) to PEGDM after 5 minutes of reaction with methacrylic anhydride at 
a 1:10 molar ratio (96% and 99% methacrylation, respectively, with no significant 
difference) [177 Lin-Gibson 2004].  Initial monomer size was not observed to impact 
resultant percent methacrylation.  The procedure described in our work for the 
preparation and purification of PEGDM is identical to a similar procedure used by Weber 
et al. for 10 kDa PEG monomers [179 Weber 2006].  Their group reports 95 ± 3% 
methacrylation of PEGDM prepared by this method as determined by 1H NMR.  
Byproducts of the microwave methacrylation reaction are methacrylic acid, which 
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should be easily removed during purification, and un-methacrylated or mono-
methacrylated PEG which should only comprise a small percentage of the final product. 
 
2.3.3 Cell Culture 
 
MIN6 cells are an immortalized mouse pancreatic β-cell line exhibiting GSIS 
comparable to native mouse β-cells.  Cells were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-
streptomycin (Invitrogen), and 0.5μg/mL Fungizone (Invitrogen).  Cells were plated on 
75 cm2 treated tissue culture flasks and incubated at ambient oxygen levels at 37°C and 
5% CO2 in humid conditions. 
 
2.3.4 Dissolved Oxygen Studies 
 
Nitrogen-purged programmable incubators were used to maintain constant 
oxygen levels for cellular studies (Napco Series 8000 WJ, Thermo Electron, USA).  All 
“high” oxygen studies were maintained at 5% CO2 and 20% oxygen.  All “low” oxygen 
studies were maintained at 5% CO2 and 1% oxygen.  To determine the corresponding 
dissolved oxygen content in culture medium during incubation, measurements were 
taken with a dissolved oxygen probe (Pasport Xplorer GLX and Pasport Dissolved Oxygen 
Sensor, PASCO, Roseville, CA, USA).  The probe was calibrated with deionized water at 
25°C.  Then, 2 mL of RPMI 1640 growth medium was placed into the well of a 24-well 
suspension plate, the probe was inserted, and the plate was incubated for at least 12 
hours.  The media remained uncovered and unagitated throughout study of both high 
and low oxygen conditions.  Incubator temperatures were maintained at 37°C.  To 
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determine if dissolved oxygen concentration was measurably impacted by cellular 
utilization of oxygen, 1 million dispersed MIN6 cells were seeded into a well and allowed 
to incubate in 2 mL of medium while dissolved oxygen concentration was measured.  
Concentrations were again recorded for both high and low oxygen conditions. 
 
2.3.5 Encapsulation of Cells 
 
Cultures of MIN6 cells were trypsinized and counted with a hemocytometer on a 
Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan).  A range of densities were seeded 
into 6-well suspension plates in a total volume of 2 mL of growth medium: 100,000 
cells/mL, 300,000 cells/mL, and 500,000 cells/mL.  Dissociated β-cells have been shown 
to rapidly lose viability and function, but can spontaneously reaggregate if allowed [272 
Matta 1994].  Therefore, cells were incubated at 37°C and 20% oxygen on a rotational 
shaker at 100 rpm for 24 hours to allow for aggregate formation. 
  To prepared vessels for capsule polymerization, clear, 1mL syringes were placed 
tip up in a rack and decapitated to remove the tapered point.  Capsules were formed in 
two steps.  Bottom halves of capsules were prepared first, by addition of 20 μL of 
photoactive PEGDM solution into the tips of standing syringes followed by 
photopolymerization by UV irradiation for 10 minutes.  Then, cells that had been 
aggregating for 24 hours were centrifuged at 200 rpm for 2 minutes and medium was 
removed.  Aggregates were re-suspended in 20 μL of photoactive PEGDM solution, with 
care taken to not dissociate the aggregates.    This volume was added into the syringe on 
top of previously polymerized capsule bottom and polymerization was continued for an 
additional 10 minutes.  In this manner, settling of suspended aggregates in their 
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respective aliquot resulted in a finished capsule with aggregates fixed in the medial 
plane.  Finished capsules were cylindrical in shape, approximately 6 mm in diameter and 
2 mm thick.  Capsules were ejected from the syringe tubes, washed with HBSS, and 
placed in 24-well suspension plates in 1 mL of growth media. 
 
2.3.6 Characterization of Aggregate Sizes 
 
Representative images of aggregates at Time 0 (initial time of encapsulation) 
were analyzed for each of the three cell densities prepared using Nikon NIS-Elements 
imaging software.  Long axis diameter and shortest orthogonal diameter were 
determined.  Average aggregate diameter and standard deviation were calculated from 
long-axis measurements.  A shape factor was also calculated as the ratio of the short-
axis to long-axis diameter for each aggregate.  The number of aggregates determined to 
be large (diameter > 150 μm) and extremely large (diameter > 250 μm) were 
additionally determined and reported along with the average size of large and 
extremely large aggregates. 
 
2.3.7 Insulin Release Studies 
 
To assess degree of device function, GSIS from encapsulated aggregates was 
measured over two weeks.  Capsules containing 200,000, 600,000 and 1 million 
aggregated cells were studied.  One day after encapsulation, culture medium was 
removed and 1 mL of a low concentration buffered glucose solution (1.1 mM) was 
introduced to each well.  Capsules were incubated for one hour before removal of this 
solution and addition of a high concentration buffered glucose solution (16.7 mM).  
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After an hour of incubation, samples from the high glucose solution were removed for 
later analysis and capsules were returned to culture medium.  These conditions were 
used to replicate a starved-state/fed-state cycle.  One set of capsules was then returned 
to incubation in the high oxygen condition while the second set was placed in low-
oxygen incubation.  Glucose stimulation was repeated in this manner every 24 hours for 
2 weeks.  At the end of the study, insulin concentration in samples was determined via 
mouse insulin ELISA assay (Mercodia, Upsalla, Sweden).  Capsules of each cellular 
density were studied in identical experimental setups.  
 
2.3.8 Construction of the Hypoxia Marker Virus 
 
A schematic of the mechanism of hypoxia signaling is shown in Figure 2.1.  The 
marker virus is a recombinant adenovirus generated using the pAdEasy-1 system 
(QBiogene, Montreal, Canada).  The red fluorescent protein is a destabilized variant of 
the DsRed protein.  The destabilized protein (termed DsRed-DR) has a portion of mouse 
ornithine decarboxylase fused to the C-terminus of the DsRed protein which contains a 
PEST sequence. The DsRed-DR sequence was removed from its vector and inserted into 
the multiple cloning site of the AdEasy transfer vector under the control of a minimal 
SV40 promoter with a trimer of the HRE sequence from murine lactate dehydrogenase 
(LDH).  A transfer vector with the LDH HRE SV40 promoter was generously donated by 
Dr. Rachel Cowen (University of Manchester, UK).  The HRE trimer upstream of the SV40 
promoter allows hypoxia-dependent transcription of the DsRed-DR protein.  After 
insertion of the DsRed-DR sequence, the transfer vector was allowed to undergo 
homologous recombination with the pAdEasy vector to produce the recombinant 
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adenoviral genome which was linearized, transferred and amplified according to the 
manufacturer’s specifications.  Following purification of the virus, a plaque assay was 
performed to determine the concentration of the resulting HRE DsRed-DR viral stocks 
which allowed infection at specified multiplicities of infection (MOI).  This value was 
determined to be 3.7 x 107 plaque-forming units per microliter. 
 
 
Figure 2.1 Schematic of a novel hypoxia detection system 
in living MIN6 cells.  In response to hypoxia, HIF-1α is 
stabilized and dimerizes with HIF-1β.  This unit initiates 
transcription at HREs in target genes producing hypoxia-




2.3.9 Fluorescent Hypoxia Detection Studies 
 
Cells were infected at an MOI of 100 by addition of the vector to the medium 
just prior to the 24 hour aggregation incubation period.  They were then encapsulated 
as described in the methods and imaged on an inverted fluorescent microscope with an 
excitation wavelength of 556 nm at a time denoted as Time 0.  One set of capsules was 
returned to the high oxygen condition while a second set was incubated in the low 
oxygen condition.  Capsules were then re-imaged approximately every 10 -12 hours for 
2 to 3 days.  Capsules containing 200,000, 600,000, and 1 million aggregated cells were 
studied.  Growth medium was replaced every 24 hours. 
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2.3.10 Statistical Analysis 
For capsules prepared at each of the described cell densities, mean insulin 
secretion at the high and low oxygen conditions were compared.  An unpaired Student’s 
t-test assuming unequal variances and with α = 0.05 was used to determine significance 
of differences between each condition.  Significance of differences in size and shape 
factor between groups was also determined by the same test.  Some measured insulin 
concentrations were at the maximum detectable limit of the performed assay.  For 
these samples, the maximum detectable value (an absorbance of 4.0 at 450 nm) was 
used.  Reported means calculated with inclusion of an estimated maximum value are 





2.4.1 Dissolved Oxygen 
 
Dissolved oxygen concentrations in RPMI 1640 medium incubated in high and 
low oxygen conditions overnight are shown in Figure 2.2A  After 13.5 hours, medium in 
the high oxygen condition exhibited a dissolved oxygen concentration of 3.9 mg/L.  This 
value was reached within the first 1.5 hours of incubation.  Medium in the low oxygen 
condition displayed a dissolved oxygen concentration of 0.6 mg/L after 13.5 hours while 
showing a more gradual decline to this value.  A dissolved oxygen concentration of 3.9 
mg/L, which represents the end concentration reached in the high oxygen condition, 
was reached within 15 minutes in the low oxygen trial.   
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Figure 2.2 A) Dissolved oxygen concentrations measured in 
2 mL of growth medium incubated at 37°C in 20% and 1% 
oxygen.  B) Dissolved oxygen concentrations measured in 2 
mL of growth medium containing 1 million MIN6 cells 
incubated in high and low oxygen conditions. 
 
 
In the second trial, 1 million MIN6 cells were added to the media in both high 
and low oxygen conditions.  Figure 2.2B shows the dissolved oxygen concentrations 
obtained from these trials.  Media containing 1 million cells displayed a dissolved oxygen 
concentration of approximately 4.0 mg/L after 13.5 hours in high oxygen incubation.  
This showed no decrease from the value observed in the high oxygen condition in the 
absence of cells.  However, after 13.5 hours of low oxygen incubation, media containing 
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1 million cells displayed a dissolved oxygen concentration of 0.2 mg/L.  This value is 
approximately one-third of the value observed for media free of cells in the low oxygen 
condition. 
 
2.4.2 Aggregate Sizes 
 
Capsules were imaged immediately following polymerization to ensure that cells 
were fully encapsulated and to determine the size of encapsulated aggregates.  
Centrifugation and re-suspension of cells during the encapsulation procedure was not 
observed to cause dissociation of aggregates.  At each encapsulated density, the bulk of 
aggregates had a diameter of 75-150 μm.  At every density, at least one exceptionally 
large aggregate (> 250 μm) was observed.  These were more frequent in higher density 
capsules, with 4 to 5 being observed in each capsule containing 1 million cells.  Capsules 
containing 1 million aggregated cells additionally displayed significant association of 
averaged-sized aggregates to form larger fused aggregate networks.   
Four representative images of encapsulated aggregates for each density were 
analyzed to better characterize aggregate size.  Table 2.1 shows average aggregate size 
for aggregates formed at each of the seeded densities.  The number and size of large 
and exceptionally large aggregates are also given, along with average aggregate size 
excluding large aggregates.  Differences in average aggregate size between all groups, 
though small, were found to be significant (p<0.05).  When excluding aggregates larger 
than 150 μm, which were less prevalent and displayed greater variability in size, 
aggregates formed from 200,000 cells still displayed a statistically significant difference 
in size from aggregates formed from 600,000 (p = 0.002) and 1 million (p = 0.0003) cells, 
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though the differences in average size was small.  Aggregates formed in the 600,000 and 
1 million cell conditions did not display a significant difference in average size when 
excluding large aggregates.  In evaluating shape, aggregates were best described as 
elliptical.  Average shape factor was determined to be 0.72 and any difference in shape 
factor among aggregates from different cell densities or between aggregates of 
different sizes was not significant. 
 



















200k 75.7*± 29.7 5 1.63 2 0.65 73.0*± 20.1 17.3-322.6 
600k 80.1*± 33.4 9 1.67 2 0.37 77.4*± 21.1 22.4-519.0 
1M 96.4*± 67.2 34 11.8 4 1.39 80.6± 30.0 27.4-835.2 
*Difference in value between groups is significant, p < 0.05. 
 
2.4.3 Glucose-Stimulated Insulin Secretion 
 
GSIS was measured at high and low oxygen for each of the cell densities 
prepared.  In high oxygen conditions, capsules containing 200,000 aggregated cells 
displayed an average (n = 4) insulin release of 6.4† μg/L (± 3.1 μg/L) at the end of two 
weeks.  Insulin release from capsules containing 600,000 (n = 3) and 1 million cells (n = 
4) was reported on average to be 10.7 μg/L (± 0.9 μg/L) and 8.2† μg/L (± 3.2 μg/L), 
respectively, at the end of two weeks.  For all three high-oxygen trials, insulin release 
remained relatively consistent and undiminished over the 14 day period.  In 1% oxygen, 
cells encapsulated at a density of 200,000 exhibited insulin release of 0.6 μg/L (± 0.4 
μg/L), cells encapsulated at a density of 600,000 exhibited insulin release of 0.3 μg/L (± 
0.1 μg/L), and cells encapsulated at a density of 1 million exhibited insulin release of 2.1 
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μg/L (± 0.7 μg/L), after 14 days.  In each case, drastic reduction in insulin release was 
observed by as early as day 2.  Figures 2.3A, B, and C show high-oxygen and low-oxygen 
insulin release from capsules containing 200,000, 600,000, and 1 million aggregated 
cells, respectively.   
 
 
Figure 2.3 Daily one hour insulin release over 2 weeks from capsules containing (A) 
200,000, (B) 600,000, and (C) 1 million aggregated MIN6 cells incubated in 20% or 1% 
oxygen.  Statistical significance of differences between high and low oxygen insulin 
secretion values is indicated by ‘*’, where p < 0.05.  Data points denoted by ‘†’ include at 
least one estimated maximum value in determination of the mean. 
  
 
Comparison of the low and high oxygen conditions showed no significant 
difference in mean insulin secretion on Day 1 for all three trials.  However, on Days 7 
and 14, secretion in the low-oxygen condition was found to be significantly lower than 
in the high-oxygen condition for each cell density tested.  (p = 0.04 and 0.02, p = 0.01 
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and 0.0008, and p = 0.03 and 0.02 for Days 7 and 14 for capsules containing 200,000, 
600,000, and 1 million cells, respectively.) 
 
2.4.4 Fluorescent Detection of Hypoxia 
 
After incubation with the hypoxia marker vector for 24 hours, capsules 
containing 200,000, 600,000, and 1 million aggregated MIN6 cells were incubated in 
either high or low oxygen.  Capsules were fluorescently imaged over 96 hours with red 
signal indicative of hypoxic stress.  For capsules incubated in high oxygen conditions, 
signal was not detected in aggregates smaller than 250 μm over the three day study 
period (Figure 2.4a1, b1, c1, d).  Signal was observed in aggregates of all sizes within 20 
hours in capsules incubated in low oxygen conditions (Figure 2.4a2, b2, c2).  In both low 
and high oxygen conditions, aggregates larger than 250 μm displayed signal in core 
regions.  With extended time, signal in low oxygen aggregates expanded to include the 
entire aggregate, but remained localized in the aggregate core in high oxygen capsules 
(Figure 2.4e, f).  The largest aggregates (> 700 μm) exhibited localized interior signal at 
the time they were encapsulated, immediately following the 24 hour aggregation period 
(Figure 2.4 g).  In continued hypoxic conditions, maximum signal expression was reached 
by 48 hours and was sustained thereafter with maintenance of the low oxygen condition.   
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Figure 2.4 Fluorescently imaged aggregates from capsules containing 
200,000 (a, bar=100μm), 600,000 (b, bar=100μm), and 1 million (c, 
bar=100μm) cells incubated in high (1) and low (2) oxygen conditions for 20 
hours.  At 20 hours in high oxygen, 250 μm aggregates (d, bar=100μm) did 
not display signal, but 500 μm aggregates showed centralized signal (e, 
bar=500μm).  At 20 hours in low oxygen, 500 μm aggregates displayed 
ubiquitous signal (f, bar=500μm), though signal onset also occurred in core 
regions.  Exceptionally large aggregates (~700 μm shown) displayed central 
signal at Time 0 (g, bar=500μm).  Fusion of smaller aggregates was noted in 





As early as 1980, transplanted encapsulated pancreatic tissue was shown to have 
potential to alleviate diabetes [164 Lim 1980].  However, long-term success of such 
devices has remained elusive, with oxygen insufficiency suspected as a primary cause.  
Currently, most studies evaluating hypoxia in tissues do so indirectly, by quantifying 
functional changes in response to varying oxygen levels, or after the fact by 
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immunostaining fixed histological sections.  However, the former approach does not 
easily account for the fact that functional changes may not be exhibited uniformly by all 
cells within a capsule, while the latter cannot indicate cellular responses at the time of 
occurrence nor retain viability of the tissue of interest.  On the other hand, knowing the 
minimum cellular oxygen requirement, one could attempt to determine whether that 
value is met within a capsule, as has been done with microelectrode measurement of 
oxygen concentration [273 Carlsson 1998] and computational modeling [151 Gross 
2007],[153 Buchwald 2009],[274 Dulong 2007].  However, although providing a good 
estimate, models are time consuming to develop and employ and must be re-adapted to 
any change in material or geometrical configuration.  Furthermore, they still cannot take 
into account every factor affecting oxygen concentration throughout a capsule as some 
are not yet even fully understood.  As an alternative approach, our fluorescent hypoxia 
marker system allows individual, living cells to report when they initiate a hypoxic stress 
response.  This method both obviates the need to measure oxygen concentration and 
allows hypoxic conditions to be detected quickly, and potentially remediated, prior to 
tissue necrosis. 
The hypoxia marker was evaluated in MIN6 aggregates encapsulated at different 
densities within crosslinked PEGDM hydrogels.  No toxic effects should be expected 
from the method of encapsulation used in this work.  Acrylated or methacrylated PEG as 
an encapsulation matrix has been shown to be supportive of a range of cell types.  PEG 
itself is highly biocompatible while the Irgacure 184 photoinitiator has been shown to 
have no influence on viability at low concentrations [180 Bryant 2000].  Bryant et al. also 
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showed that 10 minutes of UV irradiation was likewise not detrimental to cell viability, 
and report that this length of exposure is within the clinically acceptable range [180 
Bryant 2000].  Low-speed centrifugation prior to encapsulation did not result in 
aggregate disruption.   
Results from both our functional studies and hypoxia detection studies are in 
good agreement with the published literature.  Exposure of MIN6 aggregates to hypoxic 
conditions elicited an observable fluorescent response within 20 hours.  Though future 
work will focus on timing of signal initiation, extremely large aggregates (> 500 μm) 
displayed central signal at the time of encapsulation.  This indicates that signal onset 
occurs fairly quickly and agrees with Moritz et al. who found that response to hypoxia 
was observed in as little as 6 hours [275 Moritz 2002].  We also observed reduction in 
insulin secretion under hypoxic conditions, with effects beginning as early as day 2.  
Similar results have been widely reported [184 Dionne 1989],[185 Dionne 1993],[186 de 
Groot 2003].   
When comparing signal expression and insulin secretion between capsules 
containing differing densities of cells, density of seeding did not appear to directly 
influence hypoxic signaling; at 1% oxygen all aggregates appeared to display signal, 
while at 20% oxygen signal was only seen in core regions of the largest aggregates.  Thus 
aggregate size appears to exert more influence over aggregate oxygenation than overall 
cell number.  As noted, though small, differences in average aggregate size between the 
tested cell densities were determined to be significant.  However, it is unlikely that 
these average size differences contribute much to differences in signal expression and 
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insulin secretion (73 μm and 80 μm aggregates, for instance, did not exhibit differences 
in hypoxia signal expression and likely secreted insulin similarly).  The percentage of 
large and exceptionally large aggregates present in the differing populations, on the 
other hand, may have contributed more significantly.  In capsules containing 1 million 
cells, aggregates 150 μm or larger represented nearly 12% of aggregates while making 
up less than 2% of aggregates in 200,000- and 600,000-cell capsules.  Additionally, twice 
as many exceptionally large aggregates (>250 μm) were observed in 1 million-cell 
capsules.  At this size, aggregates began to display hypoxia signaling in core regions, 
even in a 20% oxygen environment, again, consistent with findings by other groups [184 
Dionne 1989],[275 Moritz 2002].  Thus, hypoxia signaling and insulin secretion were only 
indirectly affected by seeding density in capsules containing 1 million cells, insomuch 
that large aggregates were more prevalent.  We point out that in our work it was 
desirable to observe the behavior of both large and small aggregates.  However, in 
studies where stricter control of aggregate size may be important, consistency in size 
may be achieved by aggregating cells at a density of 100,000 cells per mL and then 
pooling aggregates to attain the desired number of cells per capsule. 
Close observation of insulin secretion data may point to a tempting hypothesis – 
a greater percentage of large aggregates with hypoxic core regions explains an apparent 
“diminishing returns” in insulin secretion, where capsules containing 1 million cells 
incubated in high oxygen secreted statistically similar amounts of insulin as capsules 
containing 600,000 cells.  Indeed, such an effect has been reported by Suzuki et al. [182 
Suzuki 1998].  However, as noted, a number of the measured high-oxygen insulin 
77 
concentrations were at the maximal detectable limit of the assay and were estimated in 
calculations to be the maximal value.  Because of this, accurate comparisons between 
the different seeding density groups cannot be made.  However, the effect of these 
estimated values is not so detrimental to a comparison between the high and low 
oxygen conditions, on which this study is primarily focused.  Even with relatively large 
standard deviation in some cases (attributable to small variability in cell number, 
precision of the assay, and the nature of insulin secretion), cells in high oxygen 
conditions secreted an amount of insulin that was, as calculated, significantly higher 
than cells in low oxygen conditions on Days 7 and 14.  Because any true secretion value 
could only be the same or higher than the estimated value reported in this work, the 
difference between levels of insulin secreted in high and low oxygen conditions would 
only be increased by knowledge of the more accurate value.  Thus our approach does 
not impact any conclusion drawn by a comparison of the functional effects of a 20% or 
1% oxygen environment. 
We report that hypoxia signaling was observed within 24 hours of exposure to 
low oxygen conditions while a drop in GSIS became apparent by day 2.  In this sense, 
hypoxic signaling was predictive of future device function.  Furthermore, signal onset 
was rapid enough to allow time for a remediating response prior to cell loss.  Additional 
study will be required regarding signal extinction, though preliminary observations show 
that extinction occurs within 48 hours after re-exposure to the high oxygen condition.  
We hope that with modification of MOI, this system may be tuned to achieve real-time 
signaling.  As a real-time indicator of hypoxia, the marker system might be particularly 
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useful to study of encapsulated tissues in vivo.  Strength of emission will determine if 
signal is detectable, but we would expect utility at least in small animal models with an 
implantation site near to the skin.  A possible modification in order to increase in vivo 
applicability could be to substitute a bioluminescent marker for the DsRed-DR gene used 
in this work.  Though quantification of either type of signal is difficult, current work is 
focused on measuring HIF-1α levels to compare to fluorescent intensities and 
determining threshold intensities corresponding to specific cellular responses.   
Finally, though in this work MIN6 cells were particularly suited to demonstrating 
our method of hypoxia detection, we believe that the marker system may be favorably 
utilized in other cell types as well.  We have recently, for instance, observed marker 
expression in native islets of Langerhans isolated from Balb/c mice.  In this regard, 
degree of HIF-1 expression may vary among tissue types and will have large implications 
as to whether the marker could be considered for use [275 Moritz 2002].  Nonetheless, 
recent works suggesting the role of hypoxia in directing stem cell differentiation offer 
another exciting field in which our method of hypoxia detection could be helpfully 
employed [260 Abdollahi 2010],[276 Ma 2009],[277 He 2010].  We hope to investigate 
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3.1 Abstract 
Purpose: Hypoxia is a major cause for failure of encapsulated islet grafts.  3D re-
aggregation and hypoxic preconditioning are used to help overcome this obstacle.  
However, it is still difficult to identify hypoxic cells in a 3D system.  We evaluate the 
efficacy of a fluorescent system for detecting HIF-1 activity in live β-cells.  Identification 
of HIF-1 activity and correlation with insulin secretion and viability will allow for more 
informed implant construction and better prediction of post-transplantational function. 
Methods:  MIN6 cells were infected with the marker virus and rotationally cultured to 
form clusters.  Clusters were encapsulated in PEG hydrogels and incubated in 20%, 2%, 
or 1% O2.  Gels were imaged daily for hypoxia marker signaling and for morphological 
observation.  Daily GSIS was quantified by insulin ELSIA and cell viability was assessed by 
LIVE/DEAD staining. 
Results:  Clusters cultured in 2% and 1% O2 displayed high levels HIF activity compared 
to 20% O2 clusters.  20% O2 clusters maintained viability and achieved a smooth, islet-
like morphology by Day 14.  Clusters in 2% and 1% O2 failed to associate cohesively and 
showed reduced viability.   As a whole, constructs cultured in 20% O2 exhibited 10-fold 
higher GSIS than constructs in 2% and 1% O2. 
Conclusions:  Our marker is an effective approach for identifying cellular hypoxia in 3D 
cultures.  β-cell clusters in 2% and 1% O2 are similarly affected by reduced oxygen 
tension, with HIF-1 activity correlating to reduced GSIS and impaired cell/cluster 
morphology.  Simultaneous aggregative culture and hypoxic conditioning may not be 
beneficial to β-cell transplantation. 
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3.2 Introduction 
Cell-based therapies for treatment of T1DM remain hindered by dramatically-
reduced oxygenation of excised and transplanted islets [279 Davalli 1995],[280 Carlsson 
2001],[281 Miao 2006].  While alleviating some of the difficulties associated with tissue 
transplantation, encapsulation can further decrease oxygen tension in the graft [186 de 
Groot 2003],[282 Cornolti 2009].  To reduce hypoxia-related loss of function, methods 
such as hypoxic preconditioning [283 Semenza 2011b],[284 Lo 2012] and islet 
dissociation/re-association (to produce smaller, more β-cell dense clusters) have been 
suggested [191 Cavallari 2007],[285 Schuit 2001].  Still, further advancement in islet 
transplantation will depend upon quick and accurate detection of the hypoxic state, an 
understanding of the cellular impact of and response to hypoxia, and an ability to 
remediate the hypoxic condition or avoid it in the first place.   
 Most cells exhibit substantial changes in gene expression as an adaptive 
response to oxygenation below 5 or 6%.  A majority of these changes involve 
upregulation of genes by activity of HIF-1, a heterodimeric bHLH-PAS family 
transcription factor whose presence in the cell is tightly regulated by oxygen.  
Specifically, the HIF-1α subunit is subject to rapid degradation under normoxic 
conditions, but is exponentially stabilized as oxygen becomes limited [105 Jiang 1996b].  
HIF responses serve to adapt the cell for survival in a low oxygen environment by, 
among other things, switching the cell to glycolytic metabolism, promoting local 
angiogenesis, inhibiting apoptosis, and reducing oxygen-intensive cellular activities [286 
Cassavaugh 2011].  In the insulin-secreting β-cells of the pancreas, HIF-1-induced 
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switching to glycolytic metabolism has been shown to decouple glucose sensing from 
insulin exocytosis resulting in a dramatic impairment of insulin secretion from hypoxic 
islets [195 Zehetner 2008],[196 Cantley 2009],[197 Puri 2009].  
Determining if and when insulin-producing cells become hypoxic is clearly 
important in predicting their performance.  However, identifying hypoxic cells, 
especially within 3D islet and islet-like cluster cultures, can be difficult.  Measuring 
oxygen partial pressure and modeling oxygen diffusion/consumption may help identify 
regions of low local oxygen concentration but do not identify any behavioral changes in 
the cells.  A complimentary technique is to identify HIF-1 activity, which represents a 
behavioral response to hypoxia whatever the specific oxygen concentration.  Due to its 
activity as a transcription factor and its short half-life (in normoxia, 4-8 minutes) 
[109Moroz 2009],[287 Yu 1998], direct detection of HIF-1 without compromising the cell 
and/or construct is difficult or impossible.  Furthermore, HIF responses are not 
homogeneous across cell types, with degree of stabilization and upregulated target 
genes varying between and within tissues [48 Maxwell 1993],[128 Brachen 
2006],[129Lendahl 2009].  Therefore we employ a fluorescent reporter gene system 
which indicates HIF activity in oxygen-stressed cells rather than HIF abundance.  We 
have previously reported the convenience of this approach for identifying hypoxic cells 
in β-cell clusters and allowing HIF activity to be monitored in the same sample over time 
[270 Skiles 2011a]. 
In the present work, we sought to compare HIF activity in aggregated, 
encapsulated murine β-cells to other cell properties that are impacted by hypoxia, such 
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as morphology, viability, and GSIS.  While atmospheric oxygen concentrations are 
common in cell culture, they are not representative of an implant microenvironment; 
therefore, we examined β-cell behavior in normal culture conditions (20% O2) as well as 
a pair of more physiological oxygen concentrations commonly used for hypoxic 
preconditioning (2% and 1% O2).  Given the high oxygen requirement of β-cells, elevated 
HIF activity would be expected to correlate to decreased insulin secretion and possibly 
loss of viability.  Such results would show the utility of the marker to predict functional 
changes in encapsulated β-cells and to evaluate the consequences of various oxygen 
conditions. 
 
3.3 Materials and Methods 
 
 
3.3.1 Cell Culture 
MIN6 cells were cultured in RPMI 1640 medium (Mediatech, Manassas, VA) 
supplemented with 10% fetal bovine serum (PAA, Dartmouth, MA), 1% penicillin-
streptomycin (Mediatech), 0.5 μg/mL amphotericin B (Mediatech), and 7 mM D-(+)-
glucose (Sigma-Aldrich, St. Louis, MO).  Cultures were maintained in standard incubation 
conditions at 37 °C, 5% CO2, and high humidity.  For experimental use, the cells were 
trypsinized prior to confluence, counted, and seeded into the wells of a 12-well 
suspension culture plate at a density of 400,000 cells per well in 1.7 mL of media.  
 
3.3.2 Hypoxia Marker 
 
For marker studies, the cells were infected with a hypoxia marker virus prior to 
encapsulation, as previously described [270 Skiles 2011a].  Briefly, the marker virus was 
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added to each well of dispersed cells at an MOI of 100 immediately following cell 
trypsinization and seeding.  The marker is a recombinant adenovirus generated by the 
pAD-Easy-1 system (QBiogene, Montreal, Canada) that introduces a gene coding for a 
destabilized variant of the red fluorescent protein, Ds-Red-DR under the control of a 
minimal SV40 promoter and trimer of the HRE sequence.  In an infected cell, hypoxia-
stabilized HIF-1 binds to the HRE and allows for hypoxia-induced transcription of the Ds-
Red-DR gene and subsequent fluorescent signaling. 
Following introduction of the virus, dispersed cells were incubated in rotational 
culture at 100 rpm for up to 36 hours to allow for infection and for formation of islet-
like clusters.  Clusters were then encapsulated and immediately imaged, and the gels 
were divided into three groups for rotational culture in either a 20%, 2%, or 1% oxygen 
environment.  Oxygen concentration was controlled through use of Napco Series 8000 
incubators (Thermo Fisher, Waltham, MA) with automated nitrogen purging for 
maintenance of a set oxygen percentage.  Following placement in the appropriate 
incubator, gels were fluorescently imaged daily followed by replacement of media.   
As a positive control, cells were infected with a modified marker virus containing 
a CMV promoter in place of the HRE trimer, allowing for constitutive expression of the 
marker signal, regardless of oxygen status.  As a negative control, uninfected cells were 
also fluorescently imaged.   
We have previously measured dissolved oxygen content of media incubated in 
1% O2 and observed that 24 hour incubation is sufficient to achieve a steady, 
equilibrated concentration [270 Skiles 2011a].  Therefore, in the present study, low-
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glucose media and high-glucose buffer solutions to be added to gels incubated in 2% 
and 1% O2 conditions were pre-equilibrated to 2% and 1% O2, respectively, for 24 hours 
prior to use. 
 
3.3.3 PEGDM Synthesis and Cell Encapsulation 
 
 PEGDM was synthesized from linear, 10 kDa PEG (Sigma-Aldrich) as previously 
described [270 Skiles 2011a], following a protocol adapted from Lin-Gibson et al. [177 
Lin-Gibson 2004].  Briefly, microwave methacrylation of PEG was carried out by 
irradiating a 10:1 molar ratio solution of methacrylic anhydride (Sigma-Aldrich) and PEG 
in a standard domestic microwave for 5 minutes to form PEGDM.  This was dissolved in 
excess dichloromethane (Sigma-Aldrich) then precipitated in cold, anhydrous diethyl 
ether (Sigma-Aldrich) and collected.  The precipitate was dissolved in deionized water 
and dialyzed against the same for 3 days for purification.  Purified PEGDM powder was 
collected by lyophilization. 
 A photoactive, PEGDM solution was prepared for the formation of hydrogels.  
PEGDM was dissolved in HBSS (Mediatech) to form a 10 wt% weight solution and 
Irgacure 2959 (Ciba, Basel, Switzerland) was added to 0.025 wt% as a photoinitiator.  
The solution was sterile-filtered prior to use. 
 Cell clusters were encapsulated in a two-step process.  First, the bottom half of 
the hydrogel was formed by pipetting 20 μL of photoactive PEGDM solution into a 
narrow cylindrical tube.  The tube was exposed to UV light (365 nm, ~7 mW/cm2) for 8 
minutes to initiate cross-linking.  During this time, previously aggregated MIN6 clusters 
were removed from their wells and centrifuged for 4 minutes at 210 g.  The media was 
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removed and the clusters were gently resuspended in 20 μL of photoactive PEGDM 
solution.  This volume was added on top of the first 20 μL volume and cross-linking was 
completed by an additional 8 minute UV exposure.  The hydrogels were then ejected, 
rinsed in HBSS, and placed in a 24-well plate in 1 mL of media for incubation. 
 
3.3.4 Glucose-Stimulated Insulin Secretion 
 
To evaluate GSIS from encapsulated MIN6 clusters, gels were prepared with each 
containing aggregates formed from a total of 400,000 cells.  Freshly-formed gels were 
divided into three groups and placed in 24-well plates in 1 mL of low-glucose media (2 
mM) each.  For the first day, all plates were incubated in rotational culture at 20% O2.  
After 24 hours, the media was removed and replaced with a buffered, high-glucose 
solution (16.7 mM) for one hour.  This solution was removed and frozen for future 
analysis and replaced with 1 mL of low-glucose media.  Plates were then placed in 
rotational culture at 20%, 2% or 1% O2.  Thereafter, gels were stimulated in the same 
manner every 24 hours.  Insulin concentration in media samples was quantified by 





 To assess viability of encapsulated cells, an esterase activity and plasma 
membrane permeability assay (LIVE/DEAD, Invitrogen, Grand Island, NY) was performed.  
MIN6 cells were aggregated and encapsulated as described and placed in 20%, 2% or 1% 
oxygen incubation in 1 mL of media each.  Every 24 hours, one gel from each incubator 
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was removed and stained with LIVE/DEAD reagent for 30 minutes following the 
manufacturer’s protocol.  Media was replaced in the remaining gels and they were 
returned to incubation.  Stained gels were then briefly rinsed with HBSS and 
fluorescently imaged.  Viable cells were indicated by a green cytoplasmic staining and 
dead cells were indicated by red nuclear staining.  For cells incubated in 2% and 1% O2, 
media pre-equilibrated to 2% and 1% O2, respectively, was used. 
 
3.3.6 Imaging and Statistical Analysis 
 
 Fluorescent imaging was performed on a Nikon Eclipse Ti (Nikon Instruments, 
Melville, NY) inverted, fluorescent microscope.  For fluorescent capture, care was taken 
to ensure that consistent lamp intensity and exposure settings were maintained and 
that fields were representative of the whole gel.  In marker studies, the same gels were 
tracked over time.  Image analysis was performed in NIS-Elements AR 3.0 (Nikon) 
software.  For quantitative GSIS studies, a minimum of three replicate samples were 
analyzed.  Results are reported as mean ± standard deviation.  Differences between 
values were assessed by a student’s t-test assuming unequal variances with statistical 





3.4.1 Encapsulation and Cell Morphology 
 
 Clusters of aggregated MIN6 cells were formed by 36 hour rotational culture of 
400,000 cells in low-adherence 12-well culture plates.  Previous studies indicated that 
clusters larger than 300 μm experience core hypoxia even at 20% oxygen conditions, 
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and that few clusters of this size would be formed in rotational culture of 400,000 cells 
[270 Skiles 2011a].  For each well, all clusters were collected and encapsulated in a 
single hydrogel, placed in 20%, 2% or 1% oxygen conditions, and periodically imaged 
over 2 weeks.  Hydrogels were cylindrical, approximately 2 mm high and 5 mm in 
diameter when swollen, with clusters distributed throughout (Figure 3.1).  
 
 
Figure 3.1 400,000 MIN6 cells aggregated to form islet-like clusters and encapsulated in 
a 40 μL PEGDM hydrogel.  Bar = 1 mm. 
 
 
Initially after formation, the cells were associated into small, irregularly-shaped 
clusters with individual cells remaining discernable.  By 4 days, 20% O2 clusters were 
clearly distinguishable from Day 1 clusters, with Day 7 clusters displaying a more regular, 
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ovoid shape and a smooth surface morphology akin to native islets.  Individual cells 
within the cluster could not be distinguished.  In 1% or 2% oxygen, clusters did not 
achieve a smooth, round morphology by 4, 7 or 14 days and individual cells were still β-
cells discernable within the clusters.    Clusters in 20% oxygen could be distinguished 
from those in 1% or 2% oxygen by 4 days, though not sooner.  After 2 weeks, clusters 
incubated in 20% oxygen were large, round and healthy looking with a clear islet-like 
appearance while clusters incubated in 2% and 1% oxygen appeared unchanged or 








Figure 3.2 Brightfield microscopy images of islet-like clusters for the 
analysis of morphology over 2 weeks in 20% O2, 2% O2, or 1% O2.  
Clusters incubated in 20% O2 attained a morphology similar to that of 
primary islets by 1 week and retained that morphology thereafter.  
Clusters incubated in 2% and 1% O2 never achieved a primary islet-like 








3.4.2 Hypoxia Marker 
To correlate hypoxia with cellular activity of HIF-1, a fluorescent reporter system 
was employed.  Transient infection with the marker virus allowed the cells to produce a 
red fluorescent protein under the control of active HIF-1.  If present, this signal was 
easily detected by fluorescent microscopy.  At the time of encapsulation (Time 0), no 
cells were observed to display fluorescent signal.  At the given capture settings, Clusters 
incubated in 20% oxygen exhibit few or no cells displaying fluorescent signal at the given 
capture settings over the course of the study.  Clusters incubated in 2% and 1% O2 
showed a dramatic increase in number and intensity of fluorescing cells beginning on 
Day 1 compared to 20% O2 clusters (Figure 3.3).  Intense signal in 2% O2 slightly 
preceded such signal in 1% O2.  Maximum signal intensity was reached on Day 2 or 3.  
Signal pervasiveness and intensity appeared similar between 2% and 1% O2 clusters.  
Fluorescence was heterogeneous throughout signaling clusters, with signal clearly 
identifiable in individual cells.  Though signaling cells appeared somewhat randomly 
distributed in the clusters, fluorescence was often observed in central cells of larger 
clusters.  In control studies, all CMV-DsRed-DR infected cells displayed rapid, intense 
fluorescent signaling indicating efficacy of the system and high rate of infection.  
Uninfected cells displayed no fluorescence. 
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Figure 3.3 (Top) Schematic of HIF-induced cellular 
fluorescence used to identify HIF activity in this 
study.  At sufficiently low oxygen concentrations, 
HIF-1α is stabilized, dimerizes with HIF-1β and 
binds to the HRE sequence, initiating transcription 
of the target gene, in this case Ds-Red-DR.  
(Bottom) Hypoxic signaling in islet-like clusters of 
MIN6 cells infected with the hypoxia marker virus 
for HIF-activated fluorescence.  Clusters incubated 
in 20% O2 displayed little or no fluorescence 
through the study.  Clusters incubated in 2% and 
1% O2 expressed signal by Day 2 with fluorescence 
located throughout all clusters. 
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3.4.3 Glucose-Stimulated Insulin Secretion 
 We assessed the secretory activity of MIN6 clusters incubated in 20%, 2%, and 
1% O2 for comparison to HIF-1 activity as indicated by the fluorescent marker.  These 
results are graphically represented in Figure 3.4. 
   
 
Figure 3.4 GSIS in clusters of MIN6 cells cultured in 20%, 2%, or 1% O2 
(mean ± standard deviation, n = 3).  Large asterisks indicated significant 
difference between 20% O2 and both low-oxygen conditions.  Small 
asterisks indicate significant difference between 2% and 1% O2 samples 
(p < 0.05). 
 
 
Consistent with islet-like morphological arrangement and minimal indication of 
HIF-1 activity, clusters incubated in 20% oxygen displayed high levels of insulin secretion.  
Continued increase in secretion was observed from Day 1 through Day 12.  This 
correlates well with the timeframe over which primary islet-like size and morphology 
were achieved.  On Day 12 insulin secretion plateaued, with 37.8 ± 5.5 μg of insulin 
secreted during the 1 hour stimulation period.  In clusters incubated in 1% and 2% O2, 
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very little increase in secretion from Day 1 was observed over the course of the study.  
Statistical significance between secretion from 20% clusters and secretion from low-
oxygen clusters was seen by Day 3, the time by which hypoxia signaling reached a 
maximum.  Secretion from clusters incubated in 2% O2 was slightly higher than secretion 
from clusters incubated in 1% O2.  On Day 12, one-hour secretion from clusters 
incubated in 2% and 1% O2 was measured to be 4.7 ± 0.2 μg and 4.1 ± 0.1 μg, 
respectively, equating to 8 to 9 times less insulin than by clusters in 20% O2.  As 
reported, these secretion results represent the overall insulin-producing capability of 




The viability of cells within the encapsulated clusters was examined via a 
Live/Dead esterase activity/plasma membrane integrity assay (Figure 3.5).  On Day 1, 
nearly 100% viability was observed in cells from all three oxygen conditions.  Cells 
incubated in 20% O2 maintained this level of viability throughout the 14 day study.  Loss 
of viability in a small number of cells was first observed on Day 2 in gels incubated in 1% 
oxygen and on Day 4 in gels incubated in 2% oxygen.  Through the remaining two weeks 
of the study, the appearance of non-viable cells slowly increased in both of these 
conditions; however, overall viability appeared to remain high. 
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Figure 3.5 Analysis of viability in clusters of MIN6 cells.  Cells incubated in 
20% O2 appear completely viable (green staining) over two weeks.  
Clusters incubated in 2% and 1% O2 both displayed some cell death (red 
staining, indicated with white arrows) within clusters by Day 4.  
Numerous cells appeared to be non-viable in these conditions by Day 14, 






Consistent with morphological observations, green cytoplasmic staining, 
indicating viable cells, expanded and intensified in 20% O2 clusters over the same 
timeframe in which they adopted a primary islet-like morphology.  That these clusters 
were healthy and functional is supported by their high, sustained GSIS.  Alternatively, 
green cytoplasmic staining in 2% and 1% O2 clusters was unchanged or increasingly 
diminished indicating a reduced cytoplasmic volume and reduced esterase activity.  This 
corresponded to both evidence of active HIF-1 and poor GSIS.  Representative non-
viable cells are indicated by the arrows in the figure.  Though useful as an indicator of 
change in viability between clusters incubated in 20% O2 and those incubated in hypoxic 
oxygen conditions, percent viability within the clusters was not able to be accurately 





That low oxygen tension has a profoundly negative impact on insulin secretion 
from pancreatic β-cells, both in vitro and in vivo, has been widely documented[184 
Dionne 1989],[185 Dionne 1993],[186 De Groot 2003],[280 Carlsson 2001].  However, 
the difficulty in assessing when a cell becomes hypoxic (i.e. begins to respond to 
hypoxia) on a cellular level within 3D aggregates has hindered better understanding of 
whether various physiological/culture conditions will illicit a detrimental hypoxic 
response.  Many common approaches to “identifying” hypoxia involve direct or indirect 
measurement of oxygen partial pressure or dissolved oxygen concentration.  However, 
these methods suffer from a number of drawbacks, including invasiveness and potential 
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tissue/construct damage, insufficient resolution for cellular-scale detection, 
consumption of oxygen in the detection process, requirement for tissue/construct 
sacrifice, reliance upon expensive equipment, and/or poor precision [288 Springett 
2007],[289 Grist  2010].  Furthermore, these methods focus on measurement of oxygen 
concentration but not cellular activity in response to that concentration.   
Alternatively, the method discussed in this work identifies activity of the primary 
regulator of intracellular response to hypoxia, HIF-1, and in this sense may be 
considered to truly identify hypoxic status.  This method has the added benefit that 
signaling and detection do not impact viability and that the tissue/construct need not be 
sacrificed in the detection process, as is required in histological analysis, allowing for the 
same population to be examined over time.  Our marker can be easily applied to 
monolayer culture, micromass culture, and tissue culture within 3D scaffolds to 
investigate the potential impact on oxygenation resulting from each of these conditions.  
Furthermore, because the signal protein is a direct target of HIF-1, this system is ideal 
for examining the relationship between culture conditions and various other HIF-
induced responses. 
HIF-activated pathways have been recognized as the primary mechanisms by 
which low, intracellular, oxygen concentration is translated to a program of 
transcriptional responses which result in loss of β-cell function.  We therefore 
undertook the current work based on an interest in using identification of intracellular 
HIF-1 activity as an indicator of activation of these downstream pathways.  We 
employed a previously-developed fluorescent marker system to indentify HIF-1 activity 
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in living cells which we compared to a number of physiological and functional events 
known to be impacted by hypoxia.  We showed that marker signal was induced by 
hypoxic incubation and that signal corresponded to irregular cell association and 
morphology, inability of clusters to achieve primary islet-like organization, and dramatic 
decline in GSIS.  Furthermore, hypoxic signal was apparent by Day 2, prior to the time at 
which a difference in morphology of GSIS was detectable, highlighting the use of this 
system as a predictor of cell viability and function. 
Luther et al. report that unencapsulated clusters of MIN6 cells cultured in 20% 
oxygen achieve a size and conformation similar to primary islets after 7 days [290 Luther 
2005].  In the present study, we report that encapsulated MIN6 clusters achieve primary 
islet-like size and appearance by Day 7 when cultured at 20% oxygen but not at 2% or 
1% oxygen.  Alternatively, MIN6 clusters incubated in 1% and 2% oxygen displayed 
hypoxia marker signal expression, indicative of HIF activity, and failed to achieve the 
tight, round morphology found in primary islets.  Individual cells within the clusters 
remained more distinguishable suggesting loose cell interactions rather than the tight 
interactions seen in clusters at 20% oxygen.  Proper function of pancreatic β-cells is 
heavily dependent upon cell-to-cell contact [291 Hauge-Evans 1999],[292 Lin 2011],[293 
Luther 2006].  HIF-1-induced repression of cell adhesion proteins such as E-cadherin 
through upregulation of lysyl oxidase LOX, LOXL2, SIP1 and Snail provides an appealing 
explanation for this poor association [294 Schietke 2010],[295 Evans 2007]. 
 HIF-1 also impacts insulin secretion directly by hindering metabolic pathways 
required for insulin exocytosis [283 Semenza 2011b].  Secretion of insulin from 
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pancreatic β-cells is highly coupled to glucose sensing through aerobic mitochondrial 
pathways [296 Lee 2008].  In β-cells with active HIF-1, these pathways are switched off 
resulting in severely blunted GSIS.  We found that β-cell clusters incubated in 
atmospheric oxygen conditions (20%) did not exhibit impaired GSIS, despite the 
hindrances to oxygen diffusion that encapsulation and 3D tissues provide.  However, 
when cultured in low physiological levels of oxygen, the cells exhibited clear HIF activity 
and impairment of GSIS in both 2% and 1% O2. 
 Current studies suggest that there may be benefits to dissociating islets and re-
forming them into islet-like clusters, primarily to reduce cluster diameter and improve 
oxygen transport [285 Schuit 2001],[191 Cavallari 2007].  Indeed, large diameter clusters 
can experience internal hypoxic gradients with central cells experiencing significantly 
different oxygen conditions than peripheral cells.  In previous studies, we reported that 
central cells in clusters larger than approximately 300 μm displayed increased HIF 
activity via the reporter gene, even in 20% O2 [270 Skiles 2011a].  Clusters smaller than 
this size did not exhibit the increase in 20% O2 and exhibited more uniform HIF activity 
in 2% and 1% O2.  Thus it is likely that severe oxygen gradients are not developed in 
clusters of the size examined in the current study.  Another approach to improve post-
transplantational function of β-cells is hypoxic preconditioning prior to implantation in 
order to prime them for the reduced oxygenation of the implant site [283 Semenza 
2011b],[284 Lo 2012].  Our results suggest that simultaneous aggregation and hypoxic 
conditioning do not result in maintenance of islet-like morphology or GSIS and that the 
two techniques should be applied individually or sequentially.   
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3.6 Conclusions  
 
It is clear that identifying cellular hypoxia will be beneficial to the advancement 
of cell-based diabetes therapies.  Our marker, indicating HIF-1 activity, represents an 
ideal means of making such an identification.  With this tool, we hope to establish 
correlations between β-cell oxygenation in 3D systems and β-cell function.  Having 
shown its usefulness in a model system, we intend to apply this marker to future studies 
in isolated mouse islets.  Here, we will be able to make predictions about implant 
function at various implantation sites with differing degrees of oxygenation.  We will 
also examine the correlations between HIF-1 activity, cell binding protein production 
during re-aggregation, and GSIS in 3D culture systems.  We feel that our marker system 
represents a convenient, non-invasive method of indicating intracellular HIF-1 activity 
that can serve as a much-needed tool for identifying hypoxia and examining its effects in 
current and future cell-based delivery endeavors. 
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4.1 Abstract 
ADSCs possess potent angiogenic properties and represent a source for cell-
based approaches to delivery of bioactive factors to drive vascularization of tissues.  
Hypoxic signaling appears to be largely responsible for triggering release of these 
angiogenic cytokines, including VEGF.  3D culture may promote activation of hypoxia-
induced pathways, and has furthermore been shown to enhance cell survival by 
promoting cell-cell interactions while increasing angiogenic potential.  However, the 
development of hypoxia within ADSC spheroids is difficult to characterize.  In the 
present study we investigated the impact of spheroid size on HIF-1 activity in spheroid 
cultures under atmospheric and physiological oxygen conditions using a fluorescent 
marker. Hypoxia could be induced and modulated by controlling the size of the 
spheroid; HIF-1 activity increased with spheroid size and with decreasing external 
oxygen concentration.  Furthermore, VEGF secretion was impacted by the hypoxic 
status of the culture, increasing with elevated HIF-1 activity, up to the point at which 
viability was compromised.  Together, these results suggest the ability to use 3D culture 
geometry as a means to control output of angiogenic factors from ADSCs, and imply that 
at a particular environmental oxygen concentration an optimal culture size for cytokine 
production exists.  Consideration of culture geometry and microenvironmental 
conditions at the implantation site will be important for successful realization of ADSCs 





Therapies that stimulate regeneration of damaged tissues in the body or restore 
deficient tissues with bioengineered replacements represent an appealing and emerging 
technology.  Such therapies often involve the implantation of cells or tissue into an 
ischemic wound environment,   necessitating rapid vascularization for survival and 
integration of the implant.  Indeed, diffusional mass transfer limitations restrict the 
potential size of engineered tissues and remain one of the biggest challenges to their 
clinical success [201 Lovett 2009],[203 Novosel 2011]. New strategies to enhance 
angiogenesis are required to overcome these hurdles.  
Strategies that harness the angiogenic potential of cells have shown promising 
results in recent studies. Fibroblasts [297 Levenberg 2005],[298 Kunz-Schughart 2006] 
and mesenchymal stem cells (MSCs) [232 Kim 2007],[299 Blasi 2011],[300 Halfon 2011] 
can significantly contribute to endothelial network formation and maintenance of 
microvasculature. Dispersed mesenchymal stromal cells implanted in dermal wounds 
[252 Lee 2009],[301 Nie 2011] and ischemic tissue [302 Kang  2010],[303 Bhang 2011] 
increased local levels of angiogenic cytokines and promoted increased capillary density. 
Of the potential cell candidates to be utilized for cell-based delivery, ADSCs appear 
particularly well suited for use in regenerative medicine due to their relative abundance 
and ease of culture as well as their ability to differentiate into relevant cell types in 
musculoskeletal tissue engineering (e.g., osteoblasts, chondrocytes, vascular smooth 
muscle cells). 
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The manner of cell transplantation to an injury site can impact transplant 
performance. Cells injected as a dispersion have reduced cell-cell and cell-matrix 
interactions which are important in sustaining pro-survival pathways and suppressing 
apoptosis [265 Bates 2000],[303 Bhang 2011].  Alternatively, 3D cultures retain these 
interactions, while also providing reduced oxygen tension within the cell mass which 
may prime the cells for the ischemic implantation site [267 Bhang 2012a],[268 Saleh 
2011],[269 Baraniak 2012], enhancing therapeutic effect.  For example, cord blood 
MSCs implanted as 3D spheroids upregulated expression of anti-apoptotic and 
angiogenic proteins, downregulated expression of proapoptotic proteins, and showed 
superior integration into newly forming vessels in ischemic mouse hind limbs compared 
to dispersed cells [267 Bhang 2012a].   
Oxygen gradients that form within 3D tissues are not necessarily detrimental.  In 
particular, hypoxia is responsible for initiating angiogenesis in vivo [304 Shweiki 
1992],[305 Germain 2010] through activation of HIFs and subsequent upregulation of 
bioactive factors such as VEGF [256 Forsythe 1996],[306 Maxwell 2002],[307 Fong 
2009],[308 Rey 2010].  HIF proteins are dimeric transcription factors of the bHLH-PAS 
family each composed of an α and β subunit [52 Wang 1995]. The α subunit undergoes 
oxygen-dependent hydroxylation, marking it for proteosomal degradation. When local 
oxygen concentrations are not adequate for hydroxylation to occur, the subunit is 
stabilized, pairs with a β subunit, and is free to bind to HREs found in the promoter 
region of a number of genes involved in adapting the cell for survival in low oxygen.   
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Thus, oxygen tension in 3D cell masses can contribute to activation of HIF-
regulated pathways which benefit the cells.  For instance, stabilization of HIF and VEGF 
upregulation in growing avascular tumors is well known to promote tumor 
vascularization [309 Brahimi-Horn 2001],[310 Semenza 2012b].  Similarly, endothelial 
cells cultured as spheroids were found to express higher levels of HIF-1α mRNA than 
those cultured as a monolayer under the same oxygen conditions [311 Bhang 2012b].  
Additionally, hypoxia is known to play a role in regulating cell differentiation. During 
formation of vascularized endochondral bone, regional hypoxia leads to HIF activation 
and VEGF upregulation and is integral for the formation of a cartilage template and 
synchronization of ossification with angiogenesis [312 Zelzer 2004],[313 Araldi 2010].  
Thus it is clear that identifying approaches to regulate desirable, HIF-activated signaling 
in ADSCs could provide new avenues towards creation of vascularized tissue and repair 
of critical size defects in bone. 
The present study investigates the ability to control VEGF secretion from ADSCs 
by regulating hypoxic status.  The effects of culture dimensions and incubator oxygen 
tension (atmospheric conditions as well as a pair of hypoxic levels) on angiogenic 
potential of ADSC spheroids are examined.  HIF activity within the spheroids, identified 
using a previously-described fluorescent marker system [270 Skiles 2011a], was 
compared to levels of VEGF secretion from the cells.  The impact of pelleting and 
hypoxia on cell viability and morphology were examined by staining and histological 
analysis.  Results from this study provide insight into the nature of hypoxia in 3D 
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cultures and may suggest a relevant approach for tailoring the release of angiogenic 
factors from ADSCs for improved vascularization of engineered tissues. 
 
4.3 Materials and Methods 
 
 
4.3.1 Cell Culture 
Passage 1 human ADSCs isolated from lipoaspirates were purchased from 
Invitrogen (Carlsbad, CA) and cultured in Complete MesenPRO RS™ reduced-serum 
medium supplemented with a penicillin-streptomycin solution (Mediatech, Manassas, 
VA; final concentration: 115 IU/mL penicillin, 115 μg/mL streptomycin).  This medium 
was also used throughout all experiments.  For passaging, cells were kept in a 
humidified atmosphere of 95% air and 5% carbon dioxide at 37°C.  Medium was 
changed three times a week.  At approximately 80% confluence, the cells were 
trypsinized and sub-cultured at a ratio of 1:4 until reaching passage 6, as recommended 
by the supplier.  All data included in these studies were obtained from cells between 
passages 3 and 6.  Maintenance of ADSC stemness was verified by cell-surface staining 
and flow cytometry.  Purchased, P1 cells were > 95% positive for stem cell surface 
markers CD44 and CD105.  Fluorescent antibody labeling for each (CD44: eBioscience, 
San Diego, CA; CD105: Biolegend, San Diego, CA) revealed > 95% staining for both 




Figure 4.1 Flow cytometry analysis of cell surface markers 
CD44 and CD105 in P6 ADSCs.  The cells were still >95% 
positive for both markers at passage 6, indicating 
maintenance of stemness. 
 
Nitrogen-purged, programmable incubators (Napco Series 8000, Thermo 
Electron, Waltham, Massachusetts) were used to maintain low oxygen levels for hypoxic 
culture studies.  For 2% and 1% oxygen studies, all media, buffers, and fixatives to be 
used with the cells were kept in vented tubes in the corresponding incubator overnight 
prior to use to equilibrate the solutions to the appropriate oxygen concentration. 
 
4.3.2 Hypoxia Marker Virus 
 
We have previously described the recombinant adenovirus used in this study to 
identify HIF activity [270 Skiles 2011a].  Briefly, the virus was generated using the 
pAdEasy-1 system (QBiogene, Montreal, Canada) by inserting into the vector a 
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destabilized variant of the red fluorescent protein, DsRed, (termed DsRed-DR) under the 
control of a minimal SV40 promoter and an HRE trimer.  Previous ADSC studies have 
indicated approximately 100% infection efficacy using an MOI of 80 (data not shown), 
which was utilized in these studies. 
 
4.3.3 ADSC Infection and 3D Culture Formation 
 
At approximately 80% confluence, ADSCs were trypsinized, centrifuged, 
resuspended in growth medium and counted.  For HIF activity tracking studies, hypoxia 
marker virus was added to suspended cells and gently mixed for 30 minutes.  ADSC 
spheroids of four different sizes were prepared by centrifugal pelleting.  Five thousand 
(5k), 10,000 (10k), 20,000 (20k), or 60,000 (60k) cells were pipetted into 0.5 mL, screw-
cap microcentrifuge tubes and centrifuged at 500 rcf for 2 minutes.  Spontaneous 
aggregation of the pelleted cells into cohesive spheroids occurred during overnight 
incubation at 37°C.  Spheroids of each size were then divided into three groups for 
incubation in 20%, 2%, or 1% O2.  While in incubation, the tube caps were loosened 
slightly to allow for gas transfer.  Medium was changed daily. 
Spheroids for HIF activity tracking studies were encapsulated in polyethylene 
glycol (PEG) by methods identical to those that have been published previously [270 
Skiles 2011a].  For reference, a video demonstration of this method by the authors is 







4.3.4 Quantification of Secreted VEGF 
 
 For secretion studies, spheroids were cultured in a volume of media based on 
cell number.  60k, 20k, 10k, and 5k spheroids were cultured in 900μL, 300μL, 150μL, and 
75μL of medium, respectively.  60,000 cells grown in monolayer were also cultured at 
each oxygen concentration in 1mL of medium.  Every 24 hours, the medium was 
removed from each sample and replaced with fresh medium.  Media samples were 
stored at -80°C prior to analysis.  Levels of VEGF in media samples were determined by 
ELISA (Abcam, Cambridge, MA) following the manufacturer’s instructions.  For each 
group, 6 independent samples were analyzed. 
 
4.3.5 Analysis of Cell Viability and Morphology 
 
Cell viability in ADSC spheroids was examined using a LIVE/DEAD 
cytotoxicity/viability assay (Invitrogen) and by histological examination.  The LIVE/DEAD 
kit was used according to the manufacturer’s instructions to identify esterase activity in 
live cells and loss of plasma membrane integrity in dead cells.  For histological analysis 
of morphology, spheroids were first fixed overnight in a 4% paraformaldehyde solution.  
The spheroids were then embedded in 2% agar, paraffin processed, and cut into 5μm 
sections.  Sections were stained with hematoxylin and eosin and imaged. 
 
4.3.6 Fluorescent Cell Imaging and Image Analysis 
 
 Imaging for spheroid size determination and fluorescent detection of the hypoxia 
marker was performed on a Nikon Eclipse Ti inverted fluorescent microscope (Nikon 
Instruments, Melville, NY) and image processing and analysis was performed in NIS-
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Elements software (Nikon Instruments).  Identical camera and microscope settings were 
used for each capture within a study.  Spheroids were imaged immediately following 
encapsulation and then every 24 hours thereafter.  Histological sections were imaged on 
a Nikon Optiphot-2 microscope (Nikon) fitted with a Zeiss AxioCam MRc camera (Carl 
Zeiss, Oberkochen, Germany). 
 For determination of spheroid sizes, the cross-sectional area of spheroids was 
measured in the software from representative, central-plane images of spheroids from 
each size group and the diameter of a circle with an equivalent area was calculated.  
Results are reported as the mean ± standard deviation of 6 independent samples.  To 
roughly quantify hypoxia marker signal, a fluorescent signal threshold intensity was 
applied to representative images from each group.  The area of signal meeting or 
exceeding the threshold value was compared to the total spheroid area as calculated 
from the image.  The threshold value was chosen such that no signal was detected in 
monolayer cells incubated in 20% O2, as levels of HIF-1α in these cultures were below 
detectable limits by western blotting in previous studies [315 Sahai 2012]. 
 
4.3.7 Statistical Analysis 
 
 All values are reported as mean ± standard deviation of replicate samples.  
Statistical significance of differences between samples was determined by a two-tailed 
student’s t-test assuming unequal variances (“**” indicates statistical significance at p ≤ 






4.4.1 Pelleted ADSCs form Spherical, 3D Cultures of Reproducible Size 
 
Following centrifugation, ADSCs formed a small plaque at the tip of each 
microcentrifuge tube.  After overnight incubation, the cells had spontaneously 
condensed into round spheroids with a diameter dependent upon the initial number of 
cells.  Figure 4.2A shows representative spheroids of each size at Time 0.  ADSC 
spheroids were cohesive and consistently sized within each group.  In Figure 4.2B the 
average diameter for spheroids from each study group at Time 0 (white bar) and at Day 
4 (black bar) is shown.  Minimum spheroid diameter was achieved by Day 4 with no 
further condensation observed thereafter.  5k, 10k, 20k and 60k spheroids were 362 ± 
10 μm, 454 ± 21 μm, 557 ± 20 μm, and 811 ± 37 μm in diameter, respectively, 
immediately after formation.  Spheroids diameters on Day 4 were 282 ± 6 μm, 379 ± 8 
μm, 469 ± 16 μm, and 714 ± 15 μm, respectively.   The ratio of spheroid size on Day 4 to 
initial spheroid size was similar for all size groups, ranging from approximately 78% for 
5k spheroids to 88% for 60k spheroids.  Differences in culture oxygen concentration did 
not appear to have an effect on spheroid condensation. 
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Figure 4.2 Diameter of spheroids formed by centrifugally pelleting different numbers of 
ADSCs.  Initial spheroid size could be reliably controlled by adjusting the number of cells 
pelleted (white bars).  Spheroids continued to condense for several days following initial 
formation before reaching a final minimal diameter by Day 4 (black bars).  Bar = 500μm. 
 
 
4.4.2 Spheroid Size and External O2 Concentration Affect Regional Hypoxic Signaling  
The degree of HIF activity in ADSC spheroids as indicated by red fluorescent 
signaling of the HIF marker is shown in Figure 4.3.  In spheroids of all sizes, HIF activity 
increased as incubator oxygen concentration decreased.  With decreasing oxygen, signal 
onset was more rapid and signal area and intensity were increased.  Signal also 
increased with spheroid size.  5k spheroids incubated in 20% O2 displayed little or no 
signal over 5 days.  Increasingly more signal was seen in 20% O2 spheroids as spheroid 
diameter increased.  For each oxygen concentration, signal onset was more rapid and 
signal area and intensity were higher as spheroid diameter increased.  In general, signal 
was first observed in central regions of the spheroids and remained most intense there.   
113 
 
Figure 4.3 Fluorescent DsRed signaling as an indicator of HIF activity in 5k (top left), 10k 
(top right), 20k (bottom left), and 60k (bottom right) ADSC spheroids incubated in 20%, 
2% or 1% O2.  The relative extent of signaling is quantified in the graph above each set of 
figures by applying a signal intensity threshold value.  The voided region caused by 
spheroid condensation can be seen as a ring in the hydrogel around the culture in some 





To roughly quantify the prevalence of HIF activity throughout the spheroids, the 
intensity threshold was applied to each image to identify regions exceeding it.  The 
areas of these regions were compared to the total spheroid cross-sectional area as 
determined in the software (graphs in Figure 4.3).   
The capture settings used in Figure 4.3 resulted in some spheroids with high 
levels of HIF activity being overexposed.  In this case, differences in signal intensity 
between overexposed spheroids could be resolved by reducing the camera exposure 
time (Figure 4.4). Though useful in identifying differences in HIF activity in spheroids 
that exceeded the dynamic range of capture at the given settings, apparent signal 
intensities measured from those images cannot be compared to intensities in Figure 4.3. 
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Figure 4.4 Fluorescent HIF reporter signal displayed at 1/5 the exposure length as in 
Figure 4.3 for 20k and 60k spheroids.  Differences in signal intensity between samples 
that were lost due to over-saturation are better resolved at the lower exposure.  








4.4.3 Degree of Hypoxia Impacts VEGF Secretion Profile 
 Figure 4.5 displays per-cell VEGF secretion from ADSCs in monolayers and 
spheroids cultured under different oxygen concentrations.  The calculated mean values 
and standard deviations are reported in Table 4.1.   
 
 
Figure 4.5 Levels of daily and total per-cell VEGF release from ADSC monolayers and 5k, 
10k, 20k, and 60k spheroids incubated for 5 days in 20%, 2%, or 1% O2. 
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Table 4.1 Mean values and standard deviation of VEGF release 
from ADSC cultures.  Statistical significance of differences 
between groups is indicated in Table 4.2. 
 
 
Released VEGF values represent total release over the 24 hours prior to the 
stated time point.  For each culture size, cells secreted significantly more VEGF when 
cultured in 2% or 1% O2 than in 20% O2, while little significant difference was observed 
between 2% and 1% O2.  In 2% and 1% O2 culture, monolayers and 5k spheroids 
displayed significantly elevated VEGF secretion on Day 1 followed by a sharp decline 
through Day 5.  Under the same conditions, 10k and 20k spheroids displayed a much 
more sustained elevation in VEGF secretion over 5 days, with peak secretion occurring 
on Day 2.  60k spheroids showed minor elevation of VEGF secretion on Day 1 which 
decreased over the remaining days.  Total 5-day secretion was similar in 2% and 1% O2 
culture, which were both significantly higher than 20% O2 culture.  Total per-cell VEGF 
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release increased from monolayers to 5k spheroids and from 5k to 10k spheroids then 
decreased from 10k to 20k spheroids and from 20k to 60k spheroids.  Statistical 
significance of differences in VEGF release between the different study groups can be 
found in Table 4.2.  
 
 
Table 4.2 Table indicating statistical significance of differences in mean VEGF release 
from the cultures under study.  ‘**’ indicates statistical significance at p ≤ 0.01.  ‘*’ 




5.4.4 Impact of Hypoxia on Morphology and Viability  
The morphology of stained spheroid sections is shown in Figure 4.6a-h.  On Day 1, 
all spheroids appeared cellular and cohesive throughout (a-c).  After 5 days of culture in 
20% O2, little morphological change was observed in most spheroids, though 60k 
spheroids did display a small central region of cells exhibiting cytoplasmic swelling (h).  
In 2% O2, the region with cytoplasmic swelling in 60k spheroids was much larger and 
some cellular discontinuity was observed (g).  In 1% O2, the 60k spheroids exhibited 
noticeable central tissue loss and a discontinuous core.  Cells that did inhabit the central 
region all expressed cytoplasmic swelling (f).  The 10k and 20k spheroids cultured in 2% 
and 1% O2 for 5 days exhibited only minor morphological changes in some central cells 






Figure 4.6 a-h) H&E staining of ADSC spheroid sections.  Immediately following 
formation, spheroids showed high cellularity and cohesion (a-c).  Cytoplasmic swelling 
and loss of cellular cohesion (circled regions) of central cells increased significantly with 
decreasing culture oxygenation in 60k spheroids (f-h).  10k and 20k spheroids incubated 
in 1% O2 for 5 days showed little morphological change, though cellular discontinuity 
was seen in a small central region of some 20k spheroids (d & e).  Inset: i-l) Live/Dead 
viability assessment of ADSCs in 5k (i), 10k (j), 20k (k), and 60k (l) spheroids cultured at 
1% O2 for 4 days.  Green fluorescence indicates a viable cell while red, nuclear 
fluorescence indicates a non-viable cell.  Bar = 500μm. 
 
 
A LIVE/DEAD viability stain showed that on Day 1, no dead cells were observed in 
5k, 10k, and 20k spheroids and only a small number were observed in 60k spheroids.  As 
seen in Figure 4i-l, on Day 4 no dead cells were observed in 5k spheroids and only a 
small number of dead cells were observed in 10k spheroids. 20k and 60k spheroids 
displayed relatively more non-viable cells, though these still appeared to represent a 




In this work, we examined the degree of HIF activity in ADSCs cultured as 
spheroids of different sizes in atmospheric and reduced-oxygen conditions.  We found 
that HIF activity increased in spheroids in a size-dependent manner and with decreasing 
culture oxygenation.  As a well-defined HIF target, we expected VEGF to be secreted at 
levels that increased correspondingly with HIF activity.  VEGF release profiles could be 
altered by changing the spheroid size, with 10k spheroids cultured in 2% or 1% O2 
secreting most efficiently.  That spheroids larger than 10k secreted VEGF less efficiently 
despite having greater HIF activity may be due in part to loss of cell viability as hypoxic 
severity increases, as is supported by the histology.  Our results indicate that culture 
geometry can be used a means to control cell function and stress the need to carefully 
consider tissue size and expected oxygen concentration at the implant site when 
engineering a therapeutic graft in order to maximize the benefits of HIF-activated 
pathways. 
The majority of studies in 3D stem cell cultures are carried out in atmospheric 
oxygenation or under a single “hypoxic” oxygen level (often 1% or 5% O2) and examine 
only a single culture size.  We suspected that differences in culture size and external 
oxygen concentration (even within the hypoxic range) would significantly impact culture 
oxygenation and in turn affect cellular function.  To test this, we prepared ADSC 
spheroids in a range of sizes and cultured them in three different oxygen concentrations.  
Centrifugal pelleting resulted in rapid formation of cohesive and spherical cultures while 
providing a high degree of control over spheroid size.  Additionally, a wide range of sizes 
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could be produced (including spheroids both larger and smaller than those reported in 
this study).  Culture size was highly reproducible and only dependent on the number of 
cells in the initial suspension. 
 HIF activity was monitored within the spheroids over 5 days.  As the master 
regulator of transcriptional responses to low oxygen conditions, HIF activation may be 
the most meaningful indicator of cellular hypoxia [48 Maxwell 1993].  Tracking HIF 
activity rather than oxygen concentration/distribution, as in other techniques [316 
Revsbech 1983],[317 Krihak 1996],[318 Acosta 2007], provides evidence of a behavioral 
response.  This is useful, as the oxygen concentration required to trigger a behavioral 
effect can vary between cells or even within the same cell under different 
microenvironmental conditions [126 Chi 2006],[319 Gibbs 2012].  With our HIF marker, 
image capture settings could be adjusted to match observed signal with quantified HIF-1 
levels.  Furthermore, it allowed for non-invasive identification and localization of 
hypoxia in cells within the 3D cultures and could follow HIF activity in the same sample 
over time without requiring its sacrifice.    Hydrogel encapsulation facilitated consistency 
in repeated imaging of the same sample.  While the hydrogel capsule can alter oxygen 
diffusion to some degree, the nature of qualitative trends observed between spheroids 
of different sizes were not affected.  We saw that reduced oxygenation resulted in 
increased transcriptional activity of HIF-1 in spheroids and that increasing spheroid size 
amplified this effect.  Quicker onset and increased intensity of fluorescent signaling was 
observed as culture size increased and external oxygen concentration decreased.   
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These results are in line with other studies:  HIF-1 was shown to be exponentially 
stabilized in monolayer cultures as oxygen concentration decreased from 6 to 0.5% [105 
Jiang 1996b], and higher protein levels of HIF-1α were observed in ischemic mouse limb 
buds implanted with spheroid cultures rather than dispersed HUVECs [311 Bhang 
2012b].  Similarly, small ADSC clusters (100-200μm) were shown to contain higher 
protein levels of HIF-1α than monolayer ADSCs in both 20% and 1% O2 [303 Bhang 2011].  
Our studies provided evidence on transcriptional activity of HIF-1 and examined a range 
of larger spheroid sizes (350 - 800 μm) that better represent the size of cultures 
commonly prepared in osteochondral tissue engineering. 
 Because of the potential for a capsule to impact diffusion, spheroids for VEGF 
secretion studies were not encapsulated.  Our results indicated that VEGF release is 
impacted by both external oxygenation and spheroid size, with VEGF profiles differing as 
these two parameters were altered.  In 1% and 2% O2, 10k spheroids appeared to 
provide optimal secretion.  Compared to cultures incubated in 20% O2, 60k, 20k, 10k, 
and 5k spheroids and monolayers incubated in hypoxic conditions O2 showed an 
approximate 1.5, 3.5, 5.5, 2.5, and 2.5-fold increase in VEGF production per cell, 
respectively.  However, in our HIF tracking studies, 20k and 60k spheroids displayed 
greater HIF activity than 10k spheroids.  We suspect that this is due to the severity of 
hypoxia occurring within these spheroids, especially in the spheroid core.  Severe 
hypoxia is known to result in a rapid and dramatic reduction in protein turnover, 
inhibiting protein translation and transduction [28 Hochachka 1996],[320 Pettersen 
1986],[321 Koumenis 2002].  Additionally, sudden, severe hypoxia can trigger apoptotic 
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pathways or even result in cellular necrosis [322 Greijer 2004],[323 Kiang 2006],[324 
Burton 2009].  Results from our nuclear dye exclusion assay indicated few non-viable 
cells, even in 60k spheroids cultured at 1% O2.  However, histological examination 
revealed significant acellularity and evidence of necrosis in these spheroids.  This 
interior cell death indicates severe central hypoxia and offers an explanation for the 
lower than anticipated VEGF secretion from 60k and 20k spheroids. 
 Taken together, our data suggests that the profile of VEGF release from a 3D 
ADSC spheroid is the result of a balance between two opposing effects of hypoxia:  1) 
Decreased oxygen tension resulting from cellular oxygen utilization and diffusional 
limitations stabilizes HIF-1 and induces upregulation of VEGF.  2) Excessive hypoxic 
tension, such as increasingly occurs in the interior of spheroids as size is increased, can 
lead to global protein down-regulation and cell death.  ADSCs have demonstrated pro-
angiogenic potential and may represent a preferential source for cell-based delivery in 
tissue engineering and regenerative medicine.  Furthermore, the benefits of 3D culture 
are recognized.  Considering culture geometry and expected environmental oxygen 
concentration allow for optimization of angiogenic function of 3D ADSC cultures and will 
be essential to balancing the beneficial and detrimental effects of hypoxia to achieve 
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Although oxygen tension is a potent signaling stimulus in cells, it often remains 
unconsidered in experiments carried out under standard culture conditions.  However, 
to drive restorative function of transplant tissues in vivo, proper in vitro application of 
physiological cues that contribute to regulating cell behavior will be needed.  In 
particular, physiological oxygen concentrations are well below the atmospheric 
concentration, in a range that is often viewed as hypoxic in relation to standard culture 
practices.  Within this range, HIFs govern cellular responses to local reductions in oxygen 
concentration.  These responses can result in down-regulation of typical cell functions 
and programmed cell death, or alternatively, stimulation of adaptive behaviors involved 
in beneficial processes such as growth, differentiation, and repair.  However, 
surprisingly few cell transplantation and tissue engineering efforts consider the role of 
HIF activity in tissue function, even though the intended therapeutic site is a 
physiological environment within the body.  Due to its ability to regulate cell behavior, 
cell therapies may benefit from a view that treats oxygen as similar to other paracrine 
factors: a biomolecule that must be presented to cells at the proper concentration in 
order to illicit the intended response.  However, because specific responses to a 
particular oxygen concentration can be cell-type and context dependent, 
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HIF activity may represent a more reliable indicator of microenvironmental oxygen 
conditions that affect cell behavior.  In the present work, a fluorescent reporter system 
was used to identify HIF activity in cells and demonstrate how an understanding of HIF 
activity can be used to instruct decisions that affect the therapeutic potential of 
different cell transplantation strategies. 
 HIF activity was characterized in encapsulated, 3D β-cell clusters and in 3D ADSC 
spheroids.  Transplantation of encapsulated β-cells is a regenerative medicine therapy 
aimed at restoring normoglycemia in patients with T1DM through secretion of insulin 
from the transplanted tissue which is protected from immune destruction by the 
encapsulating material.  To maintain important cell-to-cell contacts which contribute to 
β-cell survival and secretory function, β-cells are often transplanted as native, 3D islets 
or as reaggregated islet-like clusters.  Lack of vascularization, low oxygenation at the 
implant site, and oxygen gradients resulting from the 3D nature of the tissues and the 
protective capsule have all been suggested to contribute to hypoxia-induced loss of 
function in such therapies.  ADSCs have been applied in regenerative medicine therapies 
to help restore ischemic tissue injuries.  ADSCs have potent angiogenic properties that 
are upregulated under hypoxic conditions.  3D, spheroid culture of ADSCs may modulate 
their hypoxic status and contribute to their survival through cell-cell interaction.  
Inclusion of ADSC spheroids in in vitro engineered tissues or in vivo regenerating tissues 
may contribute to the formation of a pro-angiogenic niche within the tissue which could 
help drive rapid vascularization and assist tissue integration and survival.  Both of these 
therapies offer the promise of improved outcomes in patient.  Each also demonstrates a 
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role for hypoxia in the success of the therapy.  In β-cell encapsulation and 
transplantation, cellular hypoxia should be avoided in order to prevent HIF-regulated 
loss of insulin secretion, while when using ADSCs to drive angiogenesis, promotion of 
hypoxia can contribute to upregulation of HIF-regulated, pro-angiogenic behaviors.  The 
ability to identify HIF activity within cells in each of these systems can guide culturing 
and engineering decisions in order to optimize their therapeutic potential. 
 The use of a fluorescent reporter system to identify HIF activity in β-cells or 
ADSCs has not been reported previously.  The present studies indicate that the reporter 
is a viable and useful tool for determining the hypoxic status of cells used in 
regenerative therapies.  β-cells and ADSCs cultured in 1% and 2% O2, conditions under 
which HIF should be stable, exhibited fluorescent signaling indicating HIF transcriptional 
activity.  Cells cultured as monolayers in 20% O2, conditions under which HIF should not 
be stable, did not exhibit fluorescence.  Compared with other methods commonly used 
to identify HIF, such as Western blotting and immunostaining, the reporter technique 
was favorable because it allowed for repeated observation of HIF activity over time.  
Additionally, the fluorescent signal could be observed through PEGDM matrices, 
meaning that encapsulated cells did not need to be removed from the capsule in order 
for HIF activity to be examined. 
 HIF activity, indicated by the reporter, correlated well to differences in behavior 
between signaling and non-signaling tissues.  HIF activity in β-cell clusters corresponded 
to much lower GSIS than in clusters that did not display HIF activity.  Recently-
aggregated β-cell clusters that displayed fluorescent signaling also failed to achieve a 
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cohesive, islet-like morphology over time, while non-signaling clusters gradually became 
smooth and round, much like native islets.  Surprisingly, HIF activity did not appear to 
correspond to a substantial drop in viability in β-cell clusters over 2 weeks.  In ADSC 
spheroids, increased HIF activity corresponded to an increase in VEGF secretion, 
although spheroid size also appeared to indirectly effect VEGF secretion by affecting 
regional cell survival.  Intense fluorescent signaling corresponded to the appearance of 
pre-apoptotic or necrotic morphologies in large spheroids. 
 Using the HIF reporter system in 3D tissue cultures also provided information 
about how tissue size affects the formation of oxygen gradients within the tissue, and 
allowed for regional identification of heterogeneous HIF activity.  β-cell clusters 
incubated in 20% O2 that were smaller than 250-300μm did not display fluorescent 
signaling.  However, larger clusters displayed HIF activity in their central region in 20% 
O2, which increased in size as cluster size increased to maintain a signal-free peripheral 
region of consistent thickness.  Likewise, onset of fluorescent signaling in ADSC 
spheroids occurred in central regions. 
Finally, results from the present studies offer instructive suggestions about the 
design decisions for β-cell and ADSC transplantation therapies.  In β-cells, large clusters 
displayed central regional HIF activity.  Thus, it may be beneficial to utilize clusters that 
are smaller than 250μm in order to avoid hypoxia-induced loss of function.  Additionally, 
1% O2 culture induced strong HIF activity and reduced GSIS which was not remediated 
by an increase in oxygen concentration within the hypoxic range to 2% O2.  Therefore 
strategies to ensure implant-site oxygenation of >2% could be beneficial to the success 
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of β-cell therapies.  Finally, incubation in low oxygen conditions did not allow for normal 
morphological arrangement of recently-aggregated β-cell clusters.  This suggests that 
reaggregation and hypoxic preconditioning techniques should not be employed 
simultaneously in β-cells.  In ADSC, external oxygen concentration and culture size were 
both shown to contribute to pervasiveness of HIF activity in spheroids.  Increasing 
spheroid size and decreasing external oxygenation could both be used to augment HIF 
activity.  Moderate elevation of HIF activity was shown to correlate to an increase in 
VEGF secretion per cell, however, very high levels of HIF activity correlated to increased 
cell death which reduced secretion efficiency.  This suggests that for a desired 
application, optimal cell function can be driven by careful selection of culture 
parameters to effect hypoxic status.  In the study, 400μm spheroids were shown to 
produce VEGF most efficiently.  This is the first report to show that tissue size can be 
used to optimize cell-based delivery of angiogenic factors from ADSCs.  Overall, then, 
the studies reported in this work point to the important ways in which oxygen tension 
can affect cell behavior in cell transplantation therapies and highlights the usefulness of 
the fluorescent HIF reporter system.  Conclusions from these studies, and others which 
may utilize HIF tracking, should be instructive in guiding the use of appropriate 
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